

STIC-ILL

Q11. N36

(APL)

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompson A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompson A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

MM

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompson A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompson A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

QH506.14654

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompson A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompson A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

STIC-ILL

NOS

Q11.14

319734

From: Bansal, Geetha
Sent: Friday, November 10, 2000 10:56 AM
To: STIC-ILL

Please provide copies of:

1. McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8
2. King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompsett A R; Hamblin T J; Radl J; Stevenson F K
NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
3. ***Idiotypic*** vaccination in B-cell malignancies.
Bianchi A.; Massaia M.
Molecular Medicine Today, (1997) 3/10 (435-441).
4. Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompsett A; Hawkins R E
ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov 27) 772 212-26.

Thanks

Geetha Bansal

1642
CM1/8A03
305-3955

Agl-500 N484

Agl
11/14
VDO
COMPLETED
16
1.44

FILE 'HOME' ENTERED AT 10:14:06 ON 10 NOV 2000

=> file medline biosis embase scisearch uspatfull wpids

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.75	0.75

FILE 'MEDLINE' ENTERED AT 10:16:46 ON 10 NOV 2000

FILE 'BIOSIS' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 BIOSIS(R)

FILE 'EMBASE' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 Elsevier Science B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 Institute for Scientific Information (ISI) (R)

FILE 'USPATFULL' ENTERED AT 10:16:46 ON 10 NOV 2000
CA INDEXING COPYRIGHT (C) 2000 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 10:16:46 ON 10 NOV 2000
COPYRIGHT (C) 2000 DERWENT INFORMATION LTD

=> s B cell lymphoma derived immunoglobulin!

L1 0 B CELL LYMPHOMA DERIVED IMMUNOGLOBULIN!

=> s (vaccine!) and (B cell lymphoma)

L2 256 (VACCINE!) AND (B CELL LYMPHOMA)

=> s l2 and antibod?

L3 164 L2 AND ANTIBOD?

=> s l3 and multivalent vaccine

L4 4 L3 AND MULTIVALENT VACCINE

=> s l3 and (multivalent vaccine)

L5 4 L3 AND (MULTIVALENT VACCINE)

=> d l5 1-4 bib ab

L5 ANSWER 1 OF 4 USPATFULL
AN 2000:47032 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., 5045 NE. 70th St., Seattle, WA, United States 98115
Bosch, Marnix L., 2601 78th Ave. NE., Bellevue, WA, United States
98004
Strand, Kurt, 22101 SE. 32 St., Issaquah, WA, United States 98027
PI US 6051375 20000418

AI US 1999-301390 19990428 (9)
RLI Division of Ser. No. US 1996-720229, filed on 26 Sep 1996
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali R.
LREP Fish & Richardson, P.C.
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 7446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV

subfamily, including but not limited to RFHV1, RFHV2, and KSHV

Peptides,

polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 2 OF 4 USPATFULL
AN 2000:15318 USPATFULL
TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses
IN Rose, Timothy M., Seattle, WA, United States
Bosch, Marnix L., Seattle, WA, United States
Strand, Kurt, Issaquah, WA, United States
PA University of Washington, Seattle, WA, United States (U.S. corporation)
PI US 6022542 20000208
AI US 1996-720229 19960926 (8)
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali
LREP Fish & Richardson P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 6825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside

the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV

subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides,

polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 3 OF 4 USPATFULL

AN 1999:171946 USPATFULL

TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses

IN Rose, Timothy M., Seattle, WA, United States

Bosch, Marnix L., Bellevue, WA, United States

Strand, Kurt, Issaquah, WA, United States

PA The University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 6015565 19990118

AI US 1997-804439 19970221 (8)

RLI Continuation-in-part of Ser. No. WO 1996-US15702, filed on 26 Sep 1996
And a continuation-in-part of Ser. No. US 1996-720229, filed on 26 Sep 1996

PRAI US 1995-4297 19950926 (60)

US 1996-1148 19960711 (60)

DT Utility

EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Salimi, Ali

R.

LREP Wetherell, Jr., JohnFish & Richardson P.C.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 33 Drawing Figure(s); 34 Drawing Page(s)

LN.CNT 7515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV

subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides,

polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L5 ANSWER 4 OF 4 USPATFULL
 AN 1999:132226 USPATFULL
 TI **Vaccines** for treatment of lymphoma and leukemia
 IN Denney, Jr., Dan W., Redwood City, CA, United States
 PA Genitope Corporation, United States (U.S. corporation)
 PI US 5972334 19991026
 AI US 1996-761277 19961206 (8)
 RLI Continuation-in-part of Ser. No. US 1996-644664, filed on 1 May 1996,
 now patented, Pat. No. US 5776746
 DT Utility
 EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bansal, Geetha
 P.
 LREP Medlen & Carroll, LLP
 CLMN Number of Claims: 47
 ECL Exemplary Claim: 1
 DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
 LN.CNT 5339
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention provides multivalent **vaccines** for the
 treatment of B-cell malignancies (e.g., lymphomas and leukemias). The
 present invention also provides methods for the production of custom
vaccines, including multivalent **vaccines** for the
 treatment of immune cell tumors malignancies as well as methods of
 treating immune cell tumors using custom **vaccines**.

=> dhis

DHIS IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.
 For a list of commands available to you in the current file, enter
 "HELP COMMANDS" at an arrow prompt (=>).

=> d his

(FILE 'HOME' ENTERED AT 10:14:06 ON 10 NOV 2000)

FILE 'MEDLINE, BIOSIS, EMBASE, SCISEARCH, USPATFULL, WPIDS' ENTERED AT
 10:16:46 ON 10 NOV 2000

L1 0 S B CELL LYMPHOMA DERIVED IMMUNOGLOBULIN!
 L2 256 S (VACCINE!) AND (B CELL LYMPHOMA)
 L3 164 S L2 AND ANTIBOD?
 L4 4 S L3 AND MULTIVALENT VACCINE
 L5 4 S L3 AND (MULTIVALENT VACCINE)

=> s l2 and (idiotyp?)

L6 151 L2 AND (IDIOTYP?)

=> s l3 and l6

L7 116 L3 AND L6

=> s l7 and (recombinant V region!)

L8 0 L7 AND (RECOMBINANT V REGION!)

=> s l7 and (immunoglobulin!)

L9 38 L7 AND (IMMUNOGLOBULIN!)

=> dup rem l9

PROCESSING COMPLETED FOR L9
L10 35 DUP REM L9 (3 DUPLICATES REMOVED)

=> d l10 1-35 bib ab

L10 ANSWER 1 OF 35 USPATFULL
AN 2000:141878 USPATFULL
TI Recombinant anti-CD4 **antibodies** for human therapy
IN Hanna, Nabil, Olivenhain, CA, United States
Newman, Roland Anthony, San Diego, CA, United States
Reff, Mitchell Elliot, San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 6136310 20001024
AI US 1995-523894 19950906 (8)
RLI Continuation-in-part of Ser. No. US 1995-476237, filed on 7 Jun 1995,
now patented, Pat. No. US 5756096 which is a continuation-in-part of
Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No.
US
5658570 which is a continuation of Ser. No. US 1992-912292, filed on 10
Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US
1992-856281, filed on 23 Mar 1992, now abandoned which is a
continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991,
now abandoned
DT Utility
EXNAM Primary Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 32 Drawing Figure(s); 32 Drawing Page(s)
LN.CNT 3398
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric **antibodies** specific to human CD4 antigen, DNA
encoding, pharmaceutical compositions containing and use thereof as
therapeutic agents are taught. These chimeric **antibodies**
contain Old World monkey variable sequences and human constant domain
sequences, preferably human gamma 1, gamma 4 or mutated forms thereof.
These **antibodies** possess desirable therapeutic properties
including low antigenicity, reduced (or absent) T cell depleting
activity, good affinity to human CD4 and enhanced stability (in vivo
half-life).

L10 ANSWER 2 OF 35 USPATFULL
AN 2000:101879 USPATFULL
TI Enhancement of **B cell lymphoma** and tumor
resistance using **idiotype**/cytokine conjugates
IN Levy, Ronald, Stanford, CA, United States
Tao, Mi-Hua, Taipei, Taiwan, Province of China
PA The Board of Trustees of the Leland Stanford Junior University, Palo
Alto, CA, United States (U.S. corporation)
PI US 6099846 20000808
WO 9408601 19940428
AI US 1995-416787 19950414 (8)
WO 1993-US9895 19931014
19950414 PCT 371 date
19950414 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1992-961788, filed on 14 Oct 1992,
now abandoned
DT Utility
EXNAM Primary Examiner: Chan, Christina Y.; Assistant Examiner: Nolan,
Patrick
J.

LREP Morrison & Foerster LLP
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 15 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 520

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **B cell lymphoma** tumor-associated antigen or a fragment thereof containing an epitope are linked to an immune-enhancing cytokine, such as GM-CSF, IL-2, or IL-4 to form an immuno-complex. This immuno-complex elicits immune responses which are protective with respect to tumor proliferation. The linkers may be simple chemical bifunctional moieties introduced through chemical synthetic techniques or peptides introduced through recombinant methodologies. **Antibodies** immunoreactive with these immunocomplexes are also useful as passive **vaccines** and as analytical tools.

L10 ANSWER 3 OF 35 USPATFULL

AN 2000:54204 USPATFULL

TI Variable heavy and light chain regions of murine monoclonal **antibody 1F7**

IN Muller, Sybille, Lexington, KY, United States

Kohler, Heinz, Lexington, KY, United States

PA Immpheron, Inc., Lexington, KY, United States (U.S. corporation)

PI US 6057421 20000502

AI US 1997-984277 19971203 (8)

RLI Continuation-in-part of Ser. No. US 1994-351193, filed on 30 Nov 1994, now abandoned

DT Utility

EXNAM Primary Examiner: Burke, Julie

LREP Meadows, James H.

CLMN Number of Claims: 4

ECL Exemplary Claim: 1

DRWN 28 Drawing Figure(s); 23 Drawing Page(s)

LN.CNT 2137

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The amino acid sequences of variable heavy and variable light domains of

murine monoclonal **antibody 1F7** are reported. Methods of use for products containing these sequences in the diagnosis and the treatment of HIV infection and AIDS are also described.

L10 ANSWER 4 OF 35 USPATFULL

AN 2000:47032 USPATFULL

TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses

IN Rose, Timothy M., 5045 NE. 70th St., Seattle, WA, United States 98115

Bosch, Marnix L., 2601 78th Ave. NE., Bellevue, WA, United States

98004

Strand, Kurt, 22101 SE. 32 St., Issaquah, WA, United States 98027

PI US 6051375 20000418

AI US 1999-301390 19990428 (9)

RLI Division of Ser. No. US 1996-720229, filed on 26 Sep 1996 "

PRAI US 1995-4297 19950926 (60)

DT Utility

EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali R.

LREP Fish & Richardson, P.C.

CLMN Number of Claims: 3

ECL Exemplary Claim: 1

DRWN 32 Drawing Figure(s); 33 Drawing Page(s)

LN.CNT 7446

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque

nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV

subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides,

polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 5 OF 35 USPATFULL

AN 2000:24287 USPATFULL

TI Receptor specific transepithelial transport of therapeutics

IN Blumberg, Richard S., Chestnut Hill, MA, United States

Simister, Neil E., Wellesley, MA, United States

Lencer, Wayne I., Jamaica Plain, MA, United States

PA The Brigham and Women's Hospital, Inc., Boston, MA, United States (U.S. corporation)

Brandeis University, Waltham, MA, United States (U.S. corporation)

PI US 6030613 20000229

AI US 1997-899856 19970724 (8)

RLI Continuation-in-part of Ser. No. US 1995-578171, filed on 29 Dec 1995 which is a continuation-in-part of Ser. No. US 1995-374159, filed on 17 Jan 1995, now patented, Pat. No. US 5671273

DT Utility

EXNAM Primary Examiner: Cunningham, Thomas M.

LREP Wolf, Greenfield & Sacks, P.C.

CLMN Number of Claims: 34

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1591

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance

and

immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the invention relates to methods and compositions for the delivery of therapeutics conjugated to a FcRn binding partner to intestinal epithelium, mucosal epithelium and epithelium of the lung. The present invention further relates to the synthesis, preparation and use of the FcRn binding partner conjugates as, or in, pharmaceutical compositions for oral systemic delivery of drugs and **vaccines**.

L10 ANSWER 6 OF 35 USPATFULL

AN 2000:15318 USPATFULL

TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses

IN Rose, Timothy M., Seattle, WA, United States

Bosch, Marnix L., Seattle, WA, United States

Strand, Kurt, Issaquah, WA, United States

PA University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 6022542 20000208
AI US 1996-720229 19960926 (8)
PRAI US 1995-4297 19950926 (60)
DT Utility
EXNAM Primary Examiner: Mosher, Mary E.; Assistant Examiner: Salimi, Ali
LREP Fish & Richardson P.C.
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 40 Drawing Figure(s); 33 Drawing Page(s)
LN.CNT 6825

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV

subfamily, including but not limited to RFHV1, RFHV2, and KSHV

Peptides,

polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 7 OF 35 USPATFULL

AN 2000:12608 USPATFULL

TI Methods for determining the presence of carcinoma using the antigen binding region of monoclonal **antibody** BR96

IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl Erik, Seattle, WA, United States
Bruce, Kim Folger, Seattle, WA, United States
Schreiber, George J., Seattle, WA, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

PI US 6020145 20000201

AI US 1994-333840 19941103 (8)

RLI Division of Ser. No. US 1993-77253, filed on 14 Jun 1993 which is a continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993,

now

patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Merchant, Gould, Smith, Edell, Welter & Schmidt

CLMN Number of Claims: 4

ECL Exemplary Claim: 1,3

DRWN 76 Drawing Figure(s); 74 Drawing Page(s)

LN.CNT 5875

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel **antibodies**,

antibody fragments and **antibody** conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the **antibodies**, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal **antibody**, BR96; a human/murine chimeric **antibody**, ChiBR96; a F(ab')₂ fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab')₂-LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive

with

a cell membrane antigen on the surface of human carcinomas. The BR96 **antibody** and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate **antibody**-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the **antibodies** of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the **antibody** component of **antibody**-drug or **antibody**-toxin conjugates. The **antibodies** also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 8 OF 35 USPATFULL

AN 1999:171946 USPATFULL

TI Glycoprotein B of the RFHV/KSHV subfamily of herpes viruses

IN Rose, Timothy M., Seattle, WA, United States

Bosch, Marnix L., Bellevue, WA, United States

Strand, Kurt, Issaquah, WA, United States

PA The University of Washington, Seattle, WA, United States (U.S. corporation)

PI US 6015565 19990118

AI US 1997-804439 19970221 (8)

RLI Continuation-in-part of Ser. No. WO 1996-US15702, filed on 26 Sep 1996
And a continuation-in-part of Ser. No. US 1996-720229, filed on 26 Sep 1996

PRAI US 1995-4297 19950926 (60)

US 1996-1148 19960711 (60)

DT Utility

EXNAM Primary Examiner: Eisenschenk, Frank C.; Assistant Examiner: Salimi, Ali

R.

LREP Wetherell, Jr., JohnFish & Richardson P.C.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN 33 Drawing Figure(s); 34 Drawing Page(s)

LN.CNT 7515

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates to polynucleotides encoding Glycoprotein B from the RFHV/KSHV subfamily of gamma herpes viruses, three members of which are characterized in detail. DNA extracts were obtained from Macaque nemestrina and Macaque mulatta monkeys affected with retroperitoneal fibromatosis (RF), and human AIDS patients affected with Kaposi's sarcoma (KS). The extracts were amplified using consensus-degenerate oligonucleotide probes designed from known protein and DNA sequences of gamma herpes viruses. The nucleotide sequences of a 319 base pair fragment are about 76% identical between RFHV1 and KSHV, and about 60-63% identical with the closest related gamma herpes viruses outside the RFHV/KSHV subfamily. Protein sequences encoded within these fragments are about 91% identical between RFHV1 and KSHV, and <.about.65% identical to that of other gamma herpes viruses. The full-length KSHV Glycoprotein B sequence comprises a transmembrane domain near the N-terminus, and a plurality of potentially antigenic sites in the extracellular domain. Materials and methods are provided

to

characterize Glycoprotein B encoding regions of members of the RFHV/KSHV subfamily, including but not limited to RFHV1, RFHV2, and KSHV Peptides, polynucleotides, and **antibodies** of this invention can be used for diagnosing infection, and for eliciting an immune response against Glycoprotein B.

L10 ANSWER 9 OF 35 USPATFULL

AN 1999:141303 USPATFULL

TI **Antibodies** reactive with human carcinomas

IN Hellstrom, Ingegerd, Seattle, WA, United States

Hellstrom, Karl Erik, Seattle, WA, United States

Bruce, Kim Folger, Seattle, WA, United States

Schreiber, George J., Redmond, WA, United States

Siegall, Clay, Edmonds, WA, United States

McAndrew, Stephen, Newtown, PA, United States

PA Bristol-Myers Squibb Company, Princeton, NJ, United States (U.S. corporation)

PI US 5980896 19991109

AI US 1993-77253 19930614 (8)

RLI Continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993, now

patented, Pat. No. US 5491088 And Ser. No. US 1992-892501, filed on 1 Jun 1992, now abandoned which is a continuation-in-part of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned, said Ser. No. US 1993-57444, filed on 5 May 1993, now patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 544246

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Merchant, Gould, Smith, Edell, Welter & Schmidt

CLMN Number of Claims: 35

ECL Exemplary Claim: 1,16,34

DRWN 76 Drawing Figure(s); 74 Drawing Page(s)

LN.CNT 5987

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel **antibodies**,

antibody fragments and **antibody** conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the **antibodies**, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal

antibody, BR96; a human/murine chimeric **antibody**, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive

with

a cell membrane antigen on the surface of human carcinomas. The BR96 **antibody** and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate **antibody**-dependent cellular cytotoxicity and

complement-dependent cytotoxicity activity. In addition, the **antibodies** of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the **antibody** component of **antibody**-drug or **antibody**-toxin conjugates. The **antibodies** also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 10 OF 35 USPATFULL

AN 1999:137463 USPATFULL

TI Murine anti-**idiotype antibody** 3H1

IN Chatterjee, Malaya, Lexington, KY, United States
Kohler, Heinz, Lexington, KY, United States
Chatterjee, Sunil K., Lexington, KY, United States
Foon, Kenneth A., Lexington, KY, United States
PA The Board of Trustees of the University of Kentucky, Lexington, KY,
United States (U.S. corporation)
PI US 5977315 19991102
AI US 1995-579940 19951228 (8)
RLI Continuation-in-part of Ser. No. US 1994-365484, filed on 28 Dec 1994,
now abandoned
DT Utility
EXNAM Primary Examiner: Reeves, Julie
LREP Morrison & Foerster LLP
CLMN Number of Claims: 29
ECL Exemplary Claim: 1
DRWN 52 Drawing Figure(s); 43 Drawing Page(s)
LN.CNT 2698

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides a monoclonal anti-**idiotype antibody** 3H1 that escapes immune tolerance and elicits a specific immune response to CEA in mice, rabbits, monkeys, and patients with advanced CEA-associated disease. This invention also provides compositions which can be used in the detection or treatment of CEA-associated tumors mimics a specific epitope on carcinoembryonic antigen and a hybridoma that produces 3H1.

L10 ANSWER 11 OF 35 USPATFULL

AN 1999:132226 USPATFULL
TI **Vaccines** for treatment of lymphoma and leukemia
IN Denney, Jr., Dan W., Redwood City, CA, United States
PA Genitope Corporation, United States (U.S. corporation)
PI US 5972334 19991026
AI US 1996-761277 19961206 (8)
RLI Continuation-in-part of Ser. No. US 1996-644664, filed on 1 May 1996,
now patented, Pat. No. US 5776746
DT Utility
EXNAM Primary Examiner: Hutzell, Paula K.; Assistant Examiner: Bansal, Geetha P.
LREP Medlen & Carroll, LLP
CLMN Number of Claims: 47
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 5339

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides multivalent **vaccines** for the treatment of B-cell malignancies (e.g., lymphomas and leukemias). The present invention also provides methods for the production of custom **vaccines**, including multivalent **vaccines** for the treatment of immune cell tumors malignancies as well as methods of treating immune cell tumors using custom **vaccines**.

L10 ANSWER 12 OF 35 USPATFULL

AN 1999:18719 USPATFULL
TI **Antibody** conjugates reactive with human carcinomas
IN Hellstrom, Ingegerg, Seattle, WA, United States
Hellstrom, Karl Erik, Seattle, WA, United States
Bruce, Kim Folger, Seattle, WA, United States
Schreiber, George J., Seattle, WA, United States
PA Bristol-Myers Squibb Company, New York, NY, United States (U.S. corporation)
PI US 5869045 19990209
AI US 1995-459354 19950602 (8)
RLI Division of Ser. No. US 1993-77253, filed on 14 Jun 1993 which is a continuation-in-part of Ser. No. US 1993-57444, filed on 5 May 1993,
now

patented, Pat. No. US 5491088 which is a continuation of Ser. No. US 1990-544246, filed on 26 Jun 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-374947, filed on 30 Jun 1989, now abandoned

DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Ungar, Susan
LREP Merchant, Gould, Smith, Welter and Schmidt
CLMN Number of Claims: 7
ECL Exemplary Claim: 1
DRWN 75 Drawing Figure(s); 74 Drawing Page(s)
LN.CNT 5935

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to novel **antibodies**, **antibody** fragments and **antibody** conjugates and single-chain immunotoxins reactive with human carcinoma cells. More particularly, the **antibodies**, conjugates and single-chain immunotoxins of the invention include: a murine monoclonal **antibody**, BR96; a human/murine chimeric **antibody**, ChiBR96; a F(ab').sub.2 fragment of BR96; ChiBR96-PE, ChiBR96-LysPE40, ChiBR96 F(ab').sub.2 -LysPE40 and ChiBR96 Fab'-LysPE40 conjugates and recombinant BR96 sFv-PE40 immunotoxin. These molecules are reactive

with a cell membrane antigen on the surface of human carcinomas. The BR96 **antibody** and its functional equivalents, displays a high degree of selectivity for carcinoma cells and possess the ability to mediate **antibody**-dependent cellular cytotoxicity and complement-dependent cytotoxicity activity. In addition, the **antibodies** of the invention internalize within the carcinoma cells to which they bind and are therefore particularly useful for therapeutic applications, for example, as the **antibody** component of **antibody**-drug or **antibody**-toxin conjugates. The **antibodies** also have a unique feature in that they are cytotoxic when used in the unmodified form, at specified concentrations.

L10 ANSWER 13 OF 35 USPATFULL

AN 1999:7146 USPATFULL

TI Method and composition for transfer of active tumor-specific immunization from an immunized allogeneic bone marrow donor

IN Kwak, Larry W., Frederick, MD, United States
Longo, Dan L., Kensington, MD, United States

PA The United States of America as represented by the Department of Health and Human Services, Washington, DC, United States (U.S. government)

PI US 5861158 19990119

AI US 1993-153464 19931117 (8)

DT Utility

EXNAM Primary Examiner: Minnifield, Nita

LREP Needle & Rosenberg, P.C.

CLMN Number of Claims: 17

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 732

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides a method of improving a transplantation of hematopoietic cells from a donor to a recipient to treat a hematopoietic

cell tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's hematopoietic cell tumor, and transplanting the donor's immunized hematopoietic cells to the recipient. Also provided is a composition comprising purified hematopoietic cells primed to produce an immunological response to foreign tumor specific antigen. Also provided is a method of treating a tumor by the transplantation of hematopoietic

cells from a donor to a recipient to treat the tumor in the recipient comprising immunizing the donor's hematopoietic cells with an antigen specific for the recipient's tumor, and transplanting the donor's immunized hematopoietic cells to the recipient.

L10 ANSWER 14 OF 35 MEDLINE DUPLICATE 1
 AN 1999110954 MEDLINE
 DN 99110954
 TI Rapid production of specific **vaccines** for lymphoma by expression of the tumor-derived single-chain Fv epitopes in tobacco plants.
 AU McCormick A A; Kumagai M H; Hanley K; Turpen T H; Hakim I; Grill L K; Tuse D; Levy S; Levy R
 CS Biosource Technologies, Inc., 3333 Vacavalle Parkway, Suite 1000, Vacaville, CA 95688, USA.
 NC CA33399 (NCI)
 AI37219 (NIAID)
 SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, (1999 Jan 19) 96 (2) 703-8.
 Journal code: PV3. ISSN: 0027-8424.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199905
 EW 19990503
 AB Rapid production of protein-based tumor-specific **vaccines** for the treatment of malignancies is possible with the plant-based transient expression system described here. We created a modified tobamoviral vector that encodes the **idiotype**-specific single-chain Fv fragment (scFv) of the immunoglobulin from the 38C13 mouse **B cell lymphoma**. Infected Nicotiana benthamiana plants contain high levels of secreted scFv protein in the extracellular compartment. This material reacts with an anti-**idiotype antibody** by Western blotting, ELISA, and affinity chromatography, suggesting that the plant-produced 38C13 scFv protein is properly folded in solution. Mice vaccinated with the affinity-purified 38C13 scFv generate >10 micrograms/ml anti-**idiotype immunoglobulins**. These mice were protected from challenge by a lethal dose of the syngeneic 38C13 tumor, similar to mice immunized with the native 38C13 IgM-keyhole limpet hemocyanin conjugate vaccine. This rapid production system for generating tumor-specific protein **vaccines** may provide a viable strategy for the treatment of non-Hodgkin's lymphoma.

L10 ANSWER 15 OF 35 USPATFULL
 AN 1998:147025 USPATFULL
 TI Vaccine comprising anti-**idiotypic antibody** to chlamydia GLXA and process
 IN MacDonald, Alex Bruce, Amherst, MA, United States
 An, Ling-Ling, La Jolla, CA, United States
 Sutton-Stuart, Elizabeth, Amherst, MA, United States
 Whittum-Hudson, Judith A., Elkton, MD, United States
 PA Johns Hopkins University, United States (U.S. corporation)
 University of Massachusetts, United States (U.S. corporation)
 PI US 5840297 19981124
 AI US 1993-34572 19930319 (8)
 DT Utility
 EXNAM Primary Examiner: Loring, Susan A.
 LREP Cook, Paul J.
 CLMN Number of Claims: 17
 ECL Exemplary Claim: 5
 DRWN 17 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 2015

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A genus specific chlamydia vaccine is provided which comprises an anti-**idiotype antibody** capable of producing in an animal an anti-anti-**idiotypic antibody** which recognizes a glycoplipid exoantigen (GLXA) of chlamydia. The vaccine is produced by producing an **idiotypic antibody** to GLXA which, in turn, is utilized to produce the anti-**idiotypic antibody** comprising the vaccine.

L10 ANSWER 16 OF 35 USPATFULL

AN 1998:64956 USPATFULL

TI Immunogenic cancer proteins and peptides and methods of use

IN Calenoff, Emanuel, Chicago, IL, United States

PA Northwestern University, Evanston, IL, United States (U.S. corporation)

PI US 5763164 19980609

AI US 1994-191338 19940203 (8)

RLI Continuation-in-part of Ser. No. US 1993-49698, filed on 16 Apr 1993, now abandoned

DT Utility

EXNAM Primary Examiner: Jones, W. Gary; Assistant Examiner: Rees, Dianne

LREP Brinks Hofer Gilson & Lione

CLMN Number of Claims: 11

ECL Exemplary Claim: 1

DRWN 13 Drawing Figure(s); 13 Drawing Page(s)

LN.CNT 2928

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to tumor specific antigens and functional proteins of a tumor cell preparable by identifying protein presents in the tumor cell that are selectively immunogenic for tumor patients. The present invention still further provides a process of making a peptide library of tumor specific humoral antigens, a process of increasing the immunogenic specificity of a tumor-associated antigen, an assay kit for detecting the presence of an **antibody** immunoreactive with a tumor-specific antigen, and a process of making T cells sensitized to a tumor-specific antigen.

L10 ANSWER 17 OF 35 USPATFULL

AN 1998:57523 USPATFULL

TI Recombinant **antibodies** for human therapy

IN Newman, Roland A., San Diego, CA, United States

Hanna, Nabil, Olivenhain, CA, United States

Raab, Ronald W., San Diego, CA, United States

PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5756096 19980526

AI US 1995-476237 19950607 (8)

RLI Continuation-in-part of Ser. No. US 1995-379072, filed on 25 Jan 1995, now patented, Pat. No. US 5658570 which is a continuation of Ser. No.

US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.

LREP Burns, Doane, Swecker & Mathis, L.L.P.

CLMN Number of Claims: 6

ECL Exemplary Claim: 1, 4

DRWN 26 Drawing Figure(s); 26 Drawing Page(s)

LN.CNT 1919

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old

World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 18 OF 35 USPATFULL
AN 1998:51191 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5750105 19980512
AI US 1995-476349 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 5 Dec 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis LLP
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2110
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 19 OF 35 USPATFULL
AN 1998:14646 USPATFULL
TI Method for diagnosing a patient for chlamydia
IN MacDonald, Alex Bruce, Amherst, MA, United States
Stuart, Elizabeth S., Amherst, MA, United States
An, Ling Ling, La Jolla, CA, United States
Whipkey, Myron D., Portland, ME, United States
PA Animal House, Inc., Portland, ME, United States (U.S. corporation)
PI US 5716793 19980210
AI US 1995-406113 19950317 (8)
RLI Continuation-in-part of Ser. No. US 1993-34572, filed on 19 Mar 1993
DT Utility
EXNAM Primary Examiner: Spiegel, Carol A.
LREP Cook, Paul J.
CLMN Number of Claims: 10
ECL Exemplary Claim: 1
DRWN 17 Drawing Figure(s); 9 Drawing Page(s)
LN.CNT 1933
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A method of detecting chlamydia in a extracellular sample is provided which comprises contacting the sample with an **idiotypic antibody** to GLXA to form an immunocomplex and detecting the immunocomplex.

L10 ANSWER 20 OF 35 USPATFULL
AN 1998:6785 USPATFULL
TI Induction of cytotoxic T-lymphocyte responses
IN Raychaudhuri, Syamal, San Diego, CA, United States
Rastetter, William H., Rancho Santa Fe, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5709860 19980120
AI US 1994-351001 19941207 (8)

RLI Continuation-in-part of Ser. No. US 1992-919787, filed on 24 Jul 1992 which is a continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary K.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 23

ECL Exemplary Claim: 1

DRWN 19 Drawing Figure(s); 14 Drawing Page(s)

LN.CNT 1242

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

L10 ANSWER 21 OF 35 MEDLINE

AN 1999025406 MEDLINE

DN 99025406

TI DNA **vaccines** with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma [see comments].

CM Comment in: Nat Med 1998 Nov;4(11):1239-40

AU King C A; Spellerberg M B; Zhu D; Rice J; Sahota S S; Thompson A R; Hamblin T J; Radl J; Stevenson F K

CS Tenovus Laboratory, Southampton University Hospitals Trust, England.

SO NATURE MEDICINE, (1998 Nov) 4 (11) 1281-6.
Journal code: CG5. ISSN: 1078-8956.

CY United States

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals

EM 199902

EW 19990204

AB Vaccination with **idiotypic** protein protects against **B-cell lymphoma**, mainly through anti-**idiotypic** **antibody**. For use in patients, DNA **vaccines** containing single-chain Fv derived from tumor provide a convenient alternative vaccine delivery system. However, single-chain Fv sequence alone induces low anti-**idiotypic** response and poor protection against lymphoma. Fusion of the gene encoding fragment C of tetanus toxin to single-chain Fv substantially promotes the anti-**idiotypic** response and induces strong protection against **B-cell lymphoma**. The same fusion design also induces protective immunity against a surface Ig-negative myeloma. These findings indicate that fusion to a pathogen sequence allows a tumor antigen to engage diverse immune mechanisms that suppress growth. This fusion design has the added advantage of overcoming potential tolerance to tumor that may exist in patients.

L10 ANSWER 22 OF 35 USPATFULL

AN 97:114941 USPATFULL

TI Induction of cytotoxic T-lymphocyte responses

IN Raychaudhuri, Syamal, San Diego, CA, United States
Rastetter, William H., Rancho Santa Fe, CA, United States

Black, Amelia, Cardiff, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5695770 19971209
AI US 1995-472311 19950607 (8)
RLI Continuation of Ser. No. US 1994-351001, filed on 7 Dec 1994 which is a continuation-in-part of Ser. No. US 1992-919787, filed on 24 Jul 1992, now patented, Pat. No. US 5585103, issued on 17 Dec 1996 which is a continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Woodward, Michael P.; Assistant Examiner: Zeman, Mary K.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 14 Drawing Page(s)
LN.CNT 1134

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This

antigen

formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

L10 ANSWER 23 OF 35 USPATFULL

AN 97:112606 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S. corporation)
PI US 5693780 19971202
AI US 1995-481869 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now abandoned which is a continuation-in-part of Ser. No. US 1992-856281, filed on 23 Mar 1992, now abandoned which is a continuation-in-part of Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Scheiner, Toni R.; Assistant Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 16
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 1755

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and a human portion, nucleic acid encoding such **antibodies**, Old World monkey monoclonal **antibodies**, and methods for their production and use.

L10 ANSWER 24 OF 35 USPATFULL

AN 97:109699 USPATFULL
TI Immunoglobulin superantigen binding to gp 120 from HIV
IN Braun, Jonathan, Sherman Oaks, CA, United States

Goodglick, Lee A., Los Angeles, CA, United States
PA The Regents of the University of California, Oakland, CA, United States
(U.S. corporation)
PI US 5691135 19971125
AI US 1994-306116 19940914 (8)
RLI Continuation-in-part of Ser. No. US 1994-259669, filed on 14 Jun 1994,
now abandoned which is a continuation of Ser. No. US 1993-9705, filed
on 26 Jan 1993, now abandoned
DT Utility
EXNAM Primary Examiner: Nucker, Christine M.; Assistant Examiner: Stucker,
Jeffrey
LREP Knobbe Martens Olson & Bear, LLP
CLMN Number of Claims: 3
ECL Exemplary Claim: 1
DRWN 23 Drawing Figure(s); 23 Drawing Page(s)
LN.CNT 1993

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB VH3 and VH4 type **immunoglobulins** display superantigen-type
binding affinity for the HIV gp120 envelope glycoprotein. VH3 and VH4
type **antibody** molecules, including IgG and IgM, are shown to
suppress HIV infection in vivo and in vitro. Determining the level of
such **antibody** molecules is correlated to the advancement of
HIV disease state.

L10 ANSWER 25 OF 35 USPATFULL

AN 97:99175 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA IDEC Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 5681722 19971028
AI US 1995-478039 19950607 (8)
RLI Division of Ser. No. US 1995-379072, filed on 25 Jan 1995 which is a
continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now
abandoned which is a continuation-in-part of Ser. No. US 1992-856281,
filed on 23 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned
DT Utility
EXNAM Primary Examiner: Feisee, Lila; Assistant Examiner: Bansal, Geetha P.
LREP Burns, Doane, Swecker & Mathis, LLP
CLMN Number of Claims: 8
ECL Exemplary Claim: 1
DRWN 33 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 2117

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and
a human portion, nucleic acid encoding such **antibodies**, Old
World monkey monoclonal **antibodies**, and methods for their
production and use.

L10 ANSWER 26 OF 35 USPATFULL

AN 97:73287 USPATFULL
TI Recombinant **antibodies** for human therapy
IN Newman, Roland A., San Diego, CA, United States
Hanna, Nabil, Olivenhain, CA, United States
Raab, Ronald W., San Diego, CA, United States
PA Idec Pharmaceuticals Corporation, San Diego, CA, United States (U.S.
corporation)
PI US 5658570 19970819
AI US 1995-379072 19950125 (8)
RLI Continuation of Ser. No. US 1992-912292, filed on 10 Jul 1992, now

abandoned which is a continuation-in-part of Ser. No. US 1992-856281,
filed on 23 Mar 1992, now abandoned which is a continuation-in-part of
Ser. No. US 1991-735064, filed on 25 Jul 1991, now abandoned

DT Utility
EXNAM Primary Examiner: Feisee, Lila
LREP Burns, Doane, Swecker & Mathis
CLMN Number of Claims: 38
ECL Exemplary Claim: 1
DRWN 26 Drawing Figure(s); 26 Drawing Page(s)
LN.CNT 1829
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Chimeric **antibodies** including an Old World monkey portion and
a human portion, nucleic acid encoding such **antibodies**, Old
World monkey monoclonal **antibodies**, and methods for their
production and use.

L10 ANSWER 27 OF 35 USPATFULL
AN 97:70717 USPATFULL
TI Oral vaccine comprising anti-**idiotypic antibody** to
chlamydia glycolipid exoantigen and process
IN MacDonald, Alex Bruce, Hatfield, MA, United States
Whittum-Hudson, Judith A., Elkton, MD, United States
Saltzman, William Mark, Baltimore, MD, United States
PA The Johns Hopkins University, Baltimore, MD, United States (U.S.
corporation)
University of Massachusetts, Amherst, MA, United States (U.S.
corporation)
PI US 5656271 19970812
AI US 1995-466752 19950606 (8)
RLI Continuation of Ser. No. US 1994-213863, filed on 16 Mar 1994, now
abandoned which is a continuation-in-part of Ser. No. US 1993-34572,
filed on 19 Mar 1993

DT Utility
EXNAM Primary Examiner: Loring, Susan A.
CLMN Number of Claims: 15
ECL Exemplary Claim: 1
DRWN 19 Drawing Figure(s); 10 Drawing Page(s)
LN.CNT 2188
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A genus specific chlamydia oral or injectable vaccine is provided which
comprises an anti-**idiotype antibody** capable of
producing in an animal an anti-**idiotypic antibody** or
Fab fragment thereof enclosed in microspheres formed of a
pharmacologically acceptable polymer is capable of producing in an
animal an anti-anti-**idiotypic** immune response (serum
antibody, secretory **antibody** or T-cell responsee)
which recognizes a glycolipid exoantigen (GLXA) of chlamydia. The oral
or injectable vaccine is produced from an **idiotypic**
antibody to GLXA which, in turn, is utilized to produce the
anti-**idiotypic antibody**.

L10 ANSWER 28 OF 35 EMBASE COPYRIGHT 2000 ELSEVIER SCI. B.V.
AN 97316363 EMBASE
DN 1997316363
TI **Idiotypic** vaccination in B-cell malignancies.
AU Bianchi A.; Massaia M.
CS Dr. A. Bianchi, Div. Universitaria di Ematologia, DMOS, AOSGBT, Via
Genova
3, 10126 Torino, Italy. maxmass@iol.it
SO (Molecular Medicine Today, (1997) 3/10 (435-441).
Refs: 33
ISSN: 1357-4310 CODEN: MMTOFK
PUI S 1357-4310(97)01105-2
CY United Kingdom

DT Journal; General Review
FS 016 Cancer
025 Hematology
026 Immunology, Serology and Transplantation
037 Drug Literature Index

LA English

SL English

AB Immunoglobulins contain unique portions, collectively termed idiotypes, that can be recognized by the immune system. Idiotypes expressed by tumor cells in B-cell malignancies can be regarded as tumor-specific antigens and targets for vaccine immunotherapy.

Haptens and adjuvants, including cytokines, have been used in several animal models to increase idiotype immunogenicity and establish protective anti-idiotype immunity. These results have been extended by the use of DNA technology, and this has led to the development of a new generation of immunogens, namely fusion proteins and naked-DNA vaccines. The central role of antigen-presenting cells as initiators of anti-idiotype immune responses has also been recognized. Guided by the experimental data, idiotypic vaccination has come into medical use in patients with lymphoma and multiple myeloma.

L10 ANSWER 29 OF 35 USPATFULL

AN 96:116114 USPATFULL

TI Induction of cytotoxic T-lymphocyte responses

IN Raychaudhuri, Syamal, San Diego, CA, United States

Rastetter, William H., Rancho Santa Fe, CA, United States

PA IDEC Pharmaceutical Corporation, San Diego, CA, United States (U.S. corporation)

PI US 5585103 19961217

AI US 1992-919787 19920724 (7)

RLI Continuation-in-part of Ser. No. US 1991-735069, filed on 25 Jul 1991, now abandoned

DT Utility

EXNAM Primary Examiner: Mosher, Mary E.

LREP Burns, Doane, Swecker & Mathis, LLP

CLMN Number of Claims: 20

ECL Exemplary Claim: 1

DRWN 14 Drawing Figure(s); 9 Drawing Page(s)

LN.CNT 1139

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen

formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

L10 ANSWER 30 OF 35 USPATFULL

AN 95:38596 USPATFULL

TI Monoclonal antibody L53 which recognizes a human tumor-associated antigen

IN Hellstrom, Ingegerd, Seattle, WA, United States

Hellstrom, Karl E., Seattle, WA, United States

Marquardt, Hans, Mercer Island, WA, United States

Johnston, Janet, Seattle, WA, United States

PA Oncogen Limited Partnership, United States (U.S. corporation)

PI US 5411884 19950502
 AI US 1993-20256 19930218 (8)
 RLI Continuation of Ser. No. US 1990-533371, filed on 5 Jun 1990, now abandoned
 DT Utility
 EXNAM Primary Examiner: Hutzell, Paula K.
 LREP Merchant, Gould, Smith, Edell, Welter & Schmidt
 CLMN Number of Claims: 13
 ECL Exemplary Claim: 1
 DRWN No Drawings
 LN.CNT 1146
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is concerned with novel monoclonal **antibody** L53 which binds strongly to a glycoprotein antigen associated with human tumors, including carcinomas of the colon, breast, and lung, as well as melanomas. The **antibody** binds to normal human cells to a much lesser degree than to tumor cells. The **antibody** finds use in diagnostic methods for as the detection of malignant cells associated with tumors. Also disclosed is a novel 70,000-75,000 dalton glycoprotein antigen recognized by MAb L53. The L53 antigen is found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

L10 ANSWER 31 OF 35 MEDLINE
 AN 96135362 MEDLINE
 DN 96135362
 TI A genetic approach to **idiotypic** vaccination for **B** cell lymphoma.
 AU Stevenson F K; Zhu D; King C A; Ashworth L J; Kumar S; Thompson A; Hawkins R E
 CS Molecular Immunology Group, Tenovus Laboratory, Southampton University Hospitals, United Kingdom.
 SO ANNALS OF THE NEW YORK ACADEMY OF SCIENCES, (1995 Nov-27) 772 212-26.
 Ref: 23
 Journal code: 5NM. ISSN: 0077-8923.
 CY United States
 DT Journal; Article; (JOURNAL ARTICLE)
 General Review; (REVIEW)
 (REVIEW, TUTORIAL)
 LA English
 FS Priority Journals; Cancer Journals
 EM 199604
 AB **Idiotypic** immunoglobulin expressed by a B cell tumor presents a clear tumor antigen which could be attacked by vaccination of the host. Vaccination with **idiotypic** protein has been shown to induce protective immunity against lymphoma, but application to patients is limited by the requirement of "personal" **vaccines** for each patient. A genetic approach enables V-region sequences encoding **idiotypic** antigen to be rescued from tumor biopsies, and to be assembled as scFv fragments. These can be expressed in bacteria to produce recombinant protein, or used directly as naked DNA **vaccines**. Intramuscular injection of **idiotypic** DNA from a mouse B cell lymphoma induces low levels of syngeneic anti-**idiotypic antibody** in serum. Response can be stimulated by co-injection of DNA plasmids encoding either IL-2 or GM-CSF, and T cells which proliferate in response to **idiotypic** IgM are generated. However, protection against tumor appears to be blocked by continuing secretion of **idiotypic** antigen from the persisting vaccine vector, which forms immune complexes with serum **antibody**. Methods for regulating the level of scFv to engage the immune system,

but not to block the effector arm are being investigated. Similar control will be applicable to the cytokine vectors, which can deliver encoded cytokines designed to activate immune pathways for tumor destruction. Experience gained in lymphoma may be extended to other tumors with defined tumor antigens.

L10 ANSWER 32 OF 35 USPATFULL
AN 93:56702 USPATFULL
TI ~~Anti-idiotypic antibodies~~ reactive with shared
idiotopes expressed by B cell lymphomas and autoantibodies
IN Miller, Richard A., 8 Ohlone, Portola Valley, CA, United States 94025
PI US 5227159 19930713
AI US 1992-898246 19920612 (7)
RLI Continuation of Ser. No. US 1990-467405, filed on 22 Jan 1990, now
abandoned which is a continuation-in-part of Ser. No. US 1989-304745,
filed on 31 Jan 1989, now abandoned
DT Utility
EXNAM Primary Examiner: Lacey, David L.; Assistant Examiner: Budens, Robert
D.
LREP Woolcott, Kenneth J.; Burgoon, Jr., Richard P.
CLMN Number of Claims: 12
ECL Exemplary Claim: 1
DRWN 10 Drawing Figure(s); 6 Drawing Page(s)
LN.CNT 1351

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB B-cell lymphomas express surface immunoglobulin (immunoglobulin) containing unique **idiotypic** (**idiotype**) determinants which may be exploited as tumor specific markers. The inventor has produced murine monoclonal **antibodies** (MAbs) reactive with the **idiotype** marker derived from 67 patients with low grade, follicular, small cleaved cell lymphoma. Out of 199 monoclonal **antibodies**, 47 (24%) were found to react with pooled normal human serum immunoglobulin in concentrations ranging from 0.6 .mu.g/ml to 160 .mu.g/ml. Of these 40 monoclonal **antibodies**, 90% cross-reacted with **idiotype** present in normal serum in levels <50 .mu.g/ml. Thirty-two of these anti-**idiotypes** were directed against a shared idiotope expressed on another patient's lymphoma cells.

The frequency of shared idiotope expression defined by each **antibody** ranged from 0.26% to 3.9% of the B-cell lymphomas tested. A panel of five anti-**idiotype antibodies** reacted with 80% of AIDS associated lymphomas. Based on the reactivity with these monoclonal **antibodies**, tumors could be grouped into distinct families. In aggregate, these 32 monoclonal **antibodies** reacted with a total of 108 of 332 B cell lymphoma cases (32.5%), including 35 of 116 follicular, small cleaved cell lymphomas (30%). Many of these anti-shared idiotopes reacted with more than one histopathologic subtype of lymphoma. Anti-**idiotypes** have been used in B-cell lymphoma diagnosis and therapy. Moreover, applicant has discovered at least seven anti-shared **idiotype antibodies** that cross react with autoantibodies, e.g., 16.6 and RF. The development of a library of anti-**idiotypes** reactive with shared idiotopes should facilitate these clinical studies by obviating the need to develop a customized hybridoma for each patient.

L10 ANSWER 33 OF 35 MEDLINE
AN 93226047 MEDLINE
DN 93226047
TI **Idiotypic**/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma
[see comments].
CM Comment in: Nature 1993 Apr 22;362(6422):695

Comment in: Nature 1993 Aug 5;364(6437):493

AU Tao M H; Levy R

CS Department of Medicine, School of Medicine, Stanford University, California 94305.

SO ~~NATURE (1993 Apr 22) 362 (6422) 755-8~~
Journal code: NSC. ISSN: 0028-0836.

CY ENGLAND: United Kingdom

DT Journal; Article; (JOURNAL ARTICLE)

LA English

FS Priority Journals; Cancer Journals

EM 199307

AB To produce a vaccine against cancer, antigens must be found that are preferentially expressed by tumour cells and can induce an immune response against the tumour. ~~The variable regions of the immunoglobulin molecules expressed on malignant B cells (idiotypes)~~ are tumour-specific, but are weak immunogens. To induce an immune response in animals or humans, the **idiotypic** protein has therefore to be chemically coupled to a strongly immunogenic protein and mixed with an adjuvant. The resulting response can protect animals from subsequent tumour challenge, and cure animals with established tumours in combination with chemotherapy. ~~Granulocyte-macrophage colony-stimulating factor (GM-CSF)~~ augments antigen presentation in a variety of cells. Here we show that by fusing a tumour-derived **idiotype** to GM-CSF, it can be converted into a strong immunogen capable of inducing **idiotype-specific antibodies** without other carrier proteins or adjuvants and of protecting recipient animals from challenge with an otherwise lethal dose of tumour cells. This approach may be applicable to the design of **vaccines** for a variety of other diseases.

L10 ANSWER 34 OF 35 USPATFULL

AN 92:102981 USPATFULL

TI Monoclonal **antibody** to novel antigen associated with human tumors

IN Hellstrom, Ingegerd, Seattle, WA, United States
Hellstrom, Karl E., Seattle, WA, United States
Marquardt, Hans, Mercer Island, WA, United States

PA Oncogen, Seattle, WA, United States (U.S. corporation)

PI US 5171665 19921215

AI US 1989-339142 19890417 (7)

DT Utility

EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Scheiner, Toni R.

LREP Mandel, SaralynnSheldon & Mak

CLMN Number of Claims: 24

ECL Exemplary Claim: 1

DRWN No Drawings

LN.CNT 1173

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is concerned with a novel monoclonal **antibody** which binds strongly to a protein antigen associated with human tumors, including carcinomas of the colon and lung. The **antibody** binds to normal human cells to a much lesser degree than to tumor cells. The **antibody** finds use both in diagnostic methods such as the detection of malignant cells associated with tumors and in therapeutic methods for treatment of humans with tumors. Also disclosed is a novel 66,000 dalton glycoprotein antigen found on the cell surface of human tumor cells. The amino terminal amino acid sequence of this antigen is: ##STR1## in which X represents an unidentified amino acid.

L10 ANSWER 35 OF 35 USPATFULL

AN 92:61852 USPATFULL

TI Monoclonal **antibody** to novel antigen associated with human

tumors
 IN Hellstrom, Karl E., Seattle, WA, United States
 Hellstrom, Ingegerd, Seattle, WA, United States
 Marquardt, Hans, Mercer Island, WA, United States
 Yoneyama, Yoshitaka, Bellevue, WA, United States
 PA Oncogen Limited Partnership, Seattle, WA, United States (U.S.
 corporation)
 PI US 5134075 19920728
 AI US 1989-312640 19890217 (7)
 DT Utility
 EXNAM Primary Examiner: Kepplinger, Esther L.; Assistant Examiner: Bidwell,
 Carol E.
 LREP Mandel, SaraLynn
 CLMN Number of Claims: 21
 ECL Exemplary Claim: 8
 DRWN No Drawings
 LN.CNT 1097
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The present invention is concerned with a novel monoclonal
antibody which binds strongly to a protein antigen associated
 with human tumors, including carcinomas of the colon, breast, ovary and
 lung, as well as melanomas and sarcomas. The **antibody** binds to
 normal human cells to a much lesser degree than to tumor cells. The
antibody finds use both in diagnostic methods such as the
 detection of malignant cells associated with tumors and in therapeutic
 methods for treatment of humans with tumors. Also disclosed is a novel
 100,000 dalton glycoprotein antigen found on the cell surface of human
 tumor cells. The amino terminal amino acid sequence of this antigen is:
 ##STR1## in which X represents an unidentified amino acid.

=> s B cell lymphoma vaccine!

L11 0 B CELL LYMPHOMA VACCINE!

=> s vaccine comprising immunoglobulin!

L12 0 VACCINE COMPRISING IMMUNOGLOBULIN!

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:sssptal642cxy

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

***** Welcome to STN International *****

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BELLSTEIN: Reload and Implementation of a New Subject Area
NEWS 4 ZDB will be removed from STN
NEWS 5 US Patent Applications available in IFICDB, IFIPAT, and IFIUDS
NEWS 6 Records from IP.com available in CAPLUS, HCAPLUS, and ZCAPLUS
NEWS 7 BIOSIS Gene Names now available in TOXCENTER
NEWS 8 Federal Research in Progress (FEDRIP) now available
NEWS 9 New e-mail delivery for search results now available
NEWS 10 MEDLINE Reload
NEWS 11 PCTFULL has been reloaded
NEWS 12 FOREG no longer contains STANDARDS file segment
NEWS 13 USAN to be reloaded July 28, 2002;
saved answer sets no longer valid
Enhanced polymer searching in REGISTRY
NETFIRST to be removed from STN
CANCERLIT reload
NEWS 14 PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 15 NTIS has been reloaded and enhanced
NEWS 16 Aquatic Toxicity Information Retrieval (AQUIRE)
NEWS 17 now available on STN
NEWS 18 IFIPAT, IFICDB, and IFIUDS have been reloaded
NEWS 19 The MEDLINE file segment of TOXCENTER has been reloaded
NEWS 20 Sequence searching in REGISTRY enhanced
NEWS 21 JAPIO has been reloaded and enhanced
NEWS 22 Experimental properties added to the REGISTRY file
NEWS 23 CASREACT Thesaurus available in CAPLUS and CA
NEWS 24 CASREACT Enriched with Reactions from 1907 to 1985
NEWS 25 EVENTLINE has been reloaded
NEWS 26 BEILSTEIN adds new search fields
NEWS 27 Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 28 DKLIT has been renamed APOLLIT
NEWS 29 More calculated properties added to REGISTRY
NEWS 30 TIBKAT will be removed from STN
NEWS 31 CSA files on STN
NEWS 32 PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 33 TOXCENTER enhanced with additional content
NEWS 34 Adis Clinical Trials Insight now available on STN
NEWS 35 ISMEC no longer available
NEWS 36 NUTRACEUT offering one free connect hour in February 2003
NEWS 37 PHARMAML offering one free connect hour in February 2003
NEWS 38 Simultaneous left and right truncation added to COMPENDEX,
NEWS 39 EMERGY, INSPEC
NEWS 40 CANCELIT is no longer being updated
NEWS 41 METADEX enhancements
NEWS 42 FCTGEN now available on STN
NEWS 43 TEMA now available on STN
NEWS 44 NTIS now allows simultaneous left and right truncation
NEWS 45

NEWS 47 Feb 26 PCTFULL now contains images
NEWS 48 Mar 04 SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 49 Mar 19 APOLLIT offering free connect time in April 2003
NEWS 50 Mar 20 EVENTLINE will be removed from STN
NEWS 51 Mar 24 PATDPAFULL now available on STN
NEWS 52 Mar 24 Additional information for trade-named substances without structures available in REGISTRY
NEWS 53 Mar 24 Indexing from 1957 to 1966 added to records in CA/CAPLUS

NEWS EXPRESS January 6 CURRENT WINDOWS VERSION IS V6.01a.
CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP).
AND CURRENT DISCOVER FILE IS DATED 01 OCTOBER 2002
NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS INTER General Internet Information
NEWS LOGIN Welcome Banner and News Items
NEWS PHONE Direct Dial and Telecommunication Network Access to STN
NEWS WWW CAS World Wide Web Site (General Information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 11:54:07 ON 03 APR 2003

=> file medline, cancerlit, biosis, confsci, scisearch, embase, uspatfull, pctfull
COST IN U.S. DOLLARS

FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'CANCERLIT' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'BIOSIS' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'CONFSCI' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'SCISEARCH' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'EMBASE' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'USPATFULL' ENTERED AT 11:54:35 ON 03 APR 2003

FILE 'PCTFULL' ENTERED AT 11:54:35 ON 03 APR 2003

=> s multivalent or polyvalent
L1 36119 MULIVALENT OR POLYVALENT
=> s l1 and b(a)cell

2 FILES SEARCHED...
6 FILES SEARCHED...
1515 L1 AND B(A) CELL
=> s l2 and idiotyp?
L3 387 L2 AND IDIOTYP?
=> s l3 and variable (a) region
L4 231 L3 AND VARIABLE (A) REGION
'1996' NOT A VALID FIELD CODE
6 FILES SEARCHED...
L5 40 L4 NOT PY=>1996
=> dup rem l5
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.
=> dup rem l5
COMMAND INTERRUPTED
If this message appears repeatedly, please notify the Help Desk.
Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.
=> d l-40

L5 ANSWER 1 OF 40 USPATFULL
AN 95:82354 USPATFULL
TI Monoclonal antibodies that bind to soluble ICE but do not bind ICE on
IN ICE expressing B lymphocytes or basophils
PA Chang, Tse-wen, Houston, TX, United States (U.S. corporation)
PI Tanox Biosystems, Inc., 19950627
PI US 5449760
AI US 1989-320294 19890912 (7)
RLI Continuation-in-part of Ser. No. US 1988-291068, filed on 28 Dec 1988,
now abandoned which is a continuation-in-part of Ser. No. US
1988-226421, filed on 29 Jul 1988, now patented, Pat. No. US 5422258
which is a continuation-in-part of Ser. No. US 1987-140036, filed on 31
Dec 1987, now abandoned

DT Utility
FS Granted
LN.CNT 726
INCL INCLM: 530/387.300
INCLS: 530/387.300
NCL NCLM: 530/387.300
NCLS: 530/388.250; 530/389.300; 435/240.270
IC [6]
ICM: C07K016-42
ICS: C12N005-70
EXF 530/387; 530/388.250; 530/389.300; 435/240.24;
435/172.2; 435/70.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 2 OF 40 USPATFULL
AN 95:58235 USPATFULL
TI Chimeric anti-human IGE-monoclonal antibody which binds to secreted IGE
and membrane-bound IGE expressed by IGE-expressing B
cells but not to IGE bound to FC receptors on basophils
IN Chang, Tse-wen, Houston, TX, United States
PA Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)
PI US 5428133 19950627
PI US 1991-809034 19911211 (7)
ICM: C07K016-42

L5 ANSWER 3 OF 40 USPATFULL
AN 95:50082 USPATFULL
TI Methods for producing high affinity anti-human IGE-monoclonal antibodies
which binds to IGE on IGE-bearing B cells but not
basophils
IN Chang, Tse-wen, Houston, TX, United States
PA Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)
PI US 5422258 19950606
PI US 1988-226421 19880729 (7)
RLI Continuation-in-part of Ser. No. US 1987-140036, filed on 31 Dec 1987,
now abandoned

DT Utility
FS Granted
LN.CNT 1110
INCL INCLM: 435/172.200
INCLS: 530/388.250; 435/240.270; 435/070.210
NCL NCLM: 435/452.000
NCLS: 435/070.210; 530/388.250
IC [6]
ICM: C12N015-06
ICS: C12N005-20; C07K016-42
EXF 530/387; 530/388.25; 435/240.27; 435/172.2; 435/240.27; 435/70.21
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 40 USPATFULL
AN 95:47846 USPATFULL
TI Anti-idiotypic antibodies specific for the paratope of
antibodies which bind to IGE-bearing B cells but not
basophils
IN Chang, Tse-wen, Houston, TX, United States
PA Sun, Bill N., Houston, TX, United States
PI Tanox Biosystems, Inc., Houston, TX, United States (U.S. corporation)
PI US 5420251 19950530
AI US 1989-357483 19890526 (7)
RLI Continuation-in-part of Ser. No. US 1988-291068, filed on 28 Dec 1988,
now abandoned which is a continuation-in-part of Ser. No. US
1988-226421, filed on 29 Jul 1988 which is a continuation-in-part of
Ser. No. US 1987-140036, filed on 31 Dec 1987, now abandoned

DT Utility
FS Granted
LN.CNT 1365
INCL INCLM: 530/387.200
INCLS: 530/387.300; 530/388.250; 530/388.730; 435/240.270
NCL NCLM: 530/387.200
NCLS: 530/387.300; 530/388.250; 530/388.730
IC [6]
ICM: C07K016-42

ICS: C12N005-20
EXF 530/387; 530/387.2; 530/387.3; 530/388.25; 530/388.73; 435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 40 USPATFULL
AN 94:70818 USPATFULL
TI Starburst conjugates
IN Tomalia, Donald A., Midland, MI, United States
Kaplan, Donald A., Cincinnati, OH, United States
Kruper, Jr., William J., Sanford, MI, United States
Cheng, Roberta C., Midland, MI, United States
Tomlinson, Ian A., Midland, MI, United States
Fazio, Michael J., Midland, MI, United States
Hedstrand, David M., Midland, MI, United States
Wilson, Larry R., Beaverton, MI, United States
The Dow Chemical Company, Midland, MI, United States (U.S. corporation)
PA US 5338532 19940816
PI US 1991-654851
AI Continuation-in-part of Ser. No. US 1989-386049, filed on 26 Jul 1989,
RLI now abandoned which is a continuation-in-part of Ser. No. US 1987-87266,
filed on 18 Aug 1987, now abandoned which is a continuation-in-part of
Ser. No. US 1986-897455, filed on 18 Aug 1986, now abandoned
DT Utility
FS Granted
LN.CNT 2745
INCL INCLM: 424/001.490 424/078.080; 424/078.100; 424/009.000; 424/078.170;
INCLS: 424/004.000; 424/078.370; 424/001.530; 424/001.690; 424/001.650; 521/025.000;
521/028.000; 436/173.000; 436/806.000; 514/772.100; 514/772.300
NCLM: 424/001.490
NCLS: 424/001.530; 424/001.650; 424/001.690; 424/009.360; 424/009.364;
424/009.400; 424/009.600; 424/078.080; 424/078.100; 424/078.170;
424/078.370; 436/173.000; 436/806.000; 514/772.100; 514/772.300;
521/025.000; 521/028.000

IC [5]
ICM: A61K043-00
ICS: A61K031-74; A61K031-785; A61K031-80
EXF 424/9.83; 424/78.08; 424/78.1; 424/78.17; 424/78.37; 424/9; 424/639;
424/617; 424/646; 424/647; 424/648; 424/1.1; 424/4; 521/28; 521/25;
436/173; 436/806; 514/772.1; 514/772.3
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 40 USPATFULL
AN 93:22794 USPATFULL
TI Molecular recognition units
IN Rodwell, John D., Yardley, PA, United States
McKearn, Thomas J., New Hope, PA, United States
Alvarez, Vernon L., Morrisville, PA, United States
Radcliffe, Robert D., Titusville, NJ, United States
Cytogen Corporation, Princeton, NJ, United States (U.S. corporation)
PA US 5196510 19930323
AI US 1990-519702 19900507 (7)
RLI Continuation-in-part of Ser. No. US 1988-291730, filed on 29 Dec 1988,
now abandoned
DT Utility
FS Granted
LN.CNT 1684
INCL INCLM: 530/324.000
INCLS: 530/326.000; 424/001.100; 424/002.000; 436/545.000; 436/546.000
NCLM: 530/324.000
NCLS: 436/545.000; 436/546.000; 530/326.000
IC [5]
ICM: C07K007-08
ICS: C07K007-10; A61K043-00; G01N033-533
EXF 436/513; 436/545; 436/546; 530/324; 530/326; 424/2

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 40 USPATFULL
AN 91:96281 USPATFULL
TI Anti-idiotypic antibodies induced by synthetic polypeptides
IN Carson, Dennis A., Del Mar, CA, United States
Fong, Sherman, San Diego, CA, United States
Chen, Pojen P., San Diego, CA, United States
Scripps Clinic and Research Foundation, La Jolla, CA, United States
(U.S. corporation)
PA US 5068177 19911126
PI US 1985-762698 19850805 (6)
AI Continuation-in-part of Ser. No. US 1983-566172, filed on 28 Dec 1983,
RLI now abandoned
DT Utility
FS Granted
LN.CNT 2606
INCL INCLM: 435/007.920
INCLS: 435/810.000; 435/007.930; 435/965.000; 424/088.000; 436/509.000;
436/518.000; 436/539.000; 436/543.000; 436/547.000; 436/808.000;
514/002.000; 530/300.000; 530/324.000; 530/325.000; 530/326.000;
530/327.000; 530/328.000; 530/329.000; 530/330.000; 530/387.000
NCLM: 424/131.100
NCLS: 424/130.100; 424/139.100; 424/158.100; 424/185.100; 424/193.100;
424/197.110; 424/810.000; 435/007.920; 435/007.930; 435/810.000;
435/965.000; 436/509.000; 436/518.000; 436/539.000; 436/543.000;
436/547.000; 436/808.000; 514/002.000; 530/300.000; 530/324.000;
530/325.000; 530/326.000; 530/327.000; 530/328.000; 530/329.000;
530/330.000; 530/387.200; 530/387.900; 530/391.100; 530/868.000

IC [5]
ICM: G01N033-53
ICS: G01N033-543; C07K015-14; C07K007-00
EXF 435/810; 436/808
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 40 USPATFULL
AN 88:82113 USPATFULL
TI Anti-immunoglobulin toxin conjugates useful in the treatment of
IN B cell tumors
Uhr, Jonathan W., Dallas, TX, United States
Vitetta, Ellen S., Dallas, TX, United States
Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PA US 4792447 19881220
AI US 1983-498754 19830527 (6)
RLI Continuation-in-part of Ser. No. US 1981-286090, filed on 23 Jul 1981,
now abandoned
DT Utility
FS Granted
LN.CNT 893
INCL INCLM: 424/085.910
INCLS: 530/387.000
NCLM: 424/183.100
NCLS: 424/805.000; 424/809.000; 530/387.200; 530/388.730; 530/391.700;
530/862.000; 530/864.000; 530/866.000
IC [4]
ICM: A61K039-395
ICS: A61K039-44; C07K015-00; C07K017-00
EXF 424/85; 424/92; 424/87; 260/112R; 435/172.2; 530/387
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 40 USPATFULL
AN 87:53733 USPATFULL
TI Method for the preparation of anti-receptor antibodies
IN Carson, Dennis A., Del Mar, CA, United States

PA Scripps Clinic and Research Foundation, La Jolla, CA, United States
(U.S. corporation)

PI US 4683295 19870728
AI US 1984-614102 19840524 (6)
DT Utility
FS Granted
LN.CNT 1209
INCL INCLM: 530/391.000
INCLS: 530/387.000; 530/388.000; 424/085.000; 436/547.000; 436/548.000;
NCL INCLS: 435/068.000
NCLM: 424/131.100
NCLS: 435/070.300; 435/070.400; 436/547.000; 436/548.000; 530/387.200;
530/389.400; 530/389.800; 530/863.000; 530/866.000
IC [4]
ICM: C07K003-08
EXF 260/112B; 424/85; 436/547; 435/68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 40 PCTFULL COPYRIGHT 2003 Univentio
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L5 ANSWER 11 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1995029700 PCTFULL ED 20020514
TIEN SYNTHETIC VACCINE FOR PROTECTION AGAINST HUMAN IMMUNODEFICIENCY VIRUS
INFECTION
TIFR VACCIN DE SYNTHESE PROTEGEANT CONTRE L'INFECTION PAR LE VIH
IN HAYNES, Barton, F.;
PA PALKER, Thomas, J.;
LA DUKE UNIVERSITY
DT English
PI Patent
DS WO 9529700 AI 19951109
DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US5465 A 19950428
PRAI US 1994-235.305 19940429
ICM A61K039-21
ICS C07K014-155; C07K017-02; C07K019-00

L5 ANSWER 12 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1995029690 PCTFULL ED 20020514
TIEN BIOLOGICALLY ACTIVE PEPTIDES AND METHODS OF IDENTIFYING THE SAME
TIFR PEPTIDES BIOLOGIQUENT ACTIFS ET PROCEDES PERMETTANT LEUR
IDENTIFICATION
IN VON FELDT, Joan, M.;
KIEBER-EMMONS, Thomas;
WEINER, David, B.;
WILLIAMS, William, V.
PA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA;
THE WISTAR INSTITUTE;
VON FELDT, Joan, M.;
KIEBER-EMMONS, Thomas;
WEINER, David, B.;
WILLIAMS, William, V.
LA English
DT Patent
PI WO 9529690 AI 19951109
DS W: CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US5160 A 19950426
PRAI US 1994-8/235.404 19940429
ICM A61K038-00
ICS A61K038-03; A61K038-16; C07K001-00; C07K007-00; C07K007-04;
C07K007-08; C07K011-00; C07K014-00; C07K019-00; C07K016-24;
C07K016-42; C12P021-00; C12P021-02; C12P021-04

L5 ANSWER 13 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1995024221 PCTFULL ED 20020514
TIEN BIOACTIVE AND/OR TARGETED DENDRIMER CONJUGATES
IN CONJUGUES DENDRIMERES BIOACTIFS ET/OU CIBLES
TOWALIA, Donald, A.;
BAKER, James, R.;
BIELINSKA, Anna, U.;
BROTHERS, Herbert, M., II;
CHENG, Roberta, C.;
FAZIO, Michael, J.;
HEDSTRAND, David, M.;
JOHNSON, Jennifer, A.;
KAPLAN, Donald, A.;
KLAKAMP, Scott, L.;
KRUPER, William, J., Jr.;
KUKOWSKA-LATALLO, Jolanta;
MAXON, Bartley, D.;
PIEHLER, Lars, T.;
TOMLINSON, Ian, A.;
WILSON, Larry, R.;
YIN, Rui
PA THE DOW CHEMICAL COMPANY;
DENDRITECH INCORPORATED;
REGENTS OF THE UNIVERSITY OF MICHIGAN;
TOWALIA, Donald, A.;
BAKER, James, R.;
BIELINSKA, Anna, U.;
BROTHERS, Herbert, M., II;
CHENG, Roberta, C.;
FAZIO, Michael, J.;
HEDSTRAND, David, M.;
JOHNSON, Jennifer, A.;
KAPLAN, Donald, A.;
KLAKAMP, Scott, L.;
KRUPER, William, J., Jr.;
KUKOWSKA-LATALLO, Jolanta;
MAXON, Bartley, D.;
PIEHLER, Lars, T.;
TOMLINSON, Ian, A.;
WILSON, Larry, R.;
YIN, Rui
LA English
DT Patent
PI WO 9524221 AI 19950914
DS W: AU BR CA CN CZ EE FI GE HU JP KR LT LV MX NO NZ PL PT RU SI
SK UA US US US US US AT BE CH DE DK ES FR GB GR IE IT
LU MC NL PT SE
AI WO 1995-US3045 A 19950307
PRAI US 1994-8/207.494 19940307
ICM US 1994-8/316.536 19940930
ICS A61K047-48
C12N015-87

L5 ANSWER 14 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1995015979 PCTFULL ED 20020514
TIEN PRETARGETING METHODS AND COMPOUNDS
TIFR PROCEDES ET COMPOSES DE PRECIBLAGE
IN THEODORE, Louis, J.;
MEYER, Damon, L.;
MALLET, Robert, W.;
KASINA, Sudhakar;
RENO, John, M.;
AXWORTHY, Donald, B.;
GUSTAVSON, Linda, M.
NEORX CORPORATION
PA English
LA

[illegible]

AI WO 1994-1B205
PRAI US 1993-8/054.452 A 19940426
ICM C12N015-31 19930426
ICS C12Q001-68; G01N033-569; C07K013-00; C12P021-08; C12Q001-04; C12N005-12

L5 ANSWER 21 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1994025585 PCTFULL ED 20020513
TIEN TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES

TIFR ANIMAUX TRANSGENIQUES CAPABLES DE PRODUIRE DES ANTICORPS HETEROLOGUES
IN LONBERG, Nils;
PA KAY, Robert, M.
GENPHARM INTERNATIONAL, INC.;

LONBERG, Nils;

KAY, Robert, M.

LONBERG, Nils;

KAY, Robert, M.

English

Patent

DT WO 9425585

DS AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ

W: LK LU LV MG MW NL NO NZ PL PT RO RU SD SE SI SK TT UA US

UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ

CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1994-US4580 A 19940425

PRAI US 1993-8/053.131 19930426

US 1993-8/096.762 19930722

US 1993-8/155.501 19931118

US 1993-8/161.739 19931203

US 1993-8/165.699 19931210

US 1994-8/209.741 19940309

C12N015-00

ICM

L5 ANSWER 22 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1994025483 PCTFULL ED 20020513

TIEN IMMUNOTHERAPEUTIC PEPTIDES DERIVED FROM TOXIC SHOCK SYNDROME TOXIN-1, ANTIBODIES THERETO, THEIR USES IN PHARMACEUTICAL COMPOSITIONS AND DIAGNOSIS

TIFR PEPTIDES IMMUNOTHERAPEUTIQUES DERIVES DE LA TOXINE-1 DU SYNDROME DU CHOC TOXIQUE, ANTICORPS CONTRE CELLE-CI, LEURS UTILISATIONS DANS DES COMPOSITIONS PHARMACEUTIQUES ET EN DIAGNOSTIC

IN CHOW, Anthony, W.;

KUM, Winnie, W.;

PA THE UNIVERSITY OF BRITISH COLUMBIA;

CHOW, Anthony, W.;

KUM, Winnie, W.;

English

Patent

DT WO 9425483

DS AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KP KR

W: KR KZ LK LU LV MG MW NL NO NZ PL PT RO RU SD SE SK TT UA

UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1994-1B140 A 19940503

PRAI US 1993-8/058.518 19930503

ICM C07K007-08

ICS C07K013-00; C12P021-08; A61K037-02; C07K007-10; C07K007-06;

A61K039-40; G01N033-50; G01N033-68; A61K039-39

L5 ANSWER 23 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1994024164 PCTFULL ED 20020513

TIEN HUMAN MONOCLONAL ANTIBODIES AND PROCESSES AND MATERIALS FOR MAKING SUCH ANTIBODIES

TIFR ANTICORPS MONOCLONAUX HUMAINS, ET PROCEDES ET MATERIAUX DE FABRICATION

IN DE CES ANTICORPS
LEBEQUE, Serge, J., E.;

ROUSSET, Francoise, M., E.;

BANCHEREAU, Jacques

SCHERING CORPORATION;

LEBEQUE, Serge, J., E.;

ROUSSET, Francoise, M., E.;

BANCHEREAU, Jacques

English

Patent

DT WO 9424164

DS AU BB BG BR BY CA CN CZ FI GE HU JP KG KR KZ LK LV MD MG MN

W: MW NO NZ PL RO RU SD SI SK TJ TT UA US VZ VN AT BE CH DE DK

ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML

MR NE SN TD TG

AI WO 1994-US3429 A 19940406

PRAI AT 1993-93400944.0 19930409

ICM C07K015-00

ICS A61K039-395; C12P021-08

L5 ANSWER 24 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1994018345 PCTFULL ED 20020513

TIEN RECEPTOR-BINDING ANTIPROLIFERATIVE PEPTIDES

TIFR PEPTIDES ANTI-PROLIFERATIFS DE FIXATION DE RECEPTEURS

IN RENSCHLER, Markus, F.;

LEVY, Ronald;

BHATT, Ramesh, R.;

DOWER, William, J.;

AFFYMAX TECHNOLOGIES N.V.;

THE BOARD OF TRUSTEES OF THE LELAND STANFORD JR. UNIVERSITY

English

Patent

DT WO 9418345

DS AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

W: WO 1994-US1319 A 19940204

US 1993-8/014.426 19930205

US 1993-8/153.341 19931115

C12Q001-68

ICS C12N015-00; A61K037-00

L5 ANSWER 25 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1994014469 PCTFULL ED 20020513

TIEN MULTIVALENT AB1 ANTIBODIES AS VACCINES

TIFR ANTICORPS AB1 MULTIVALENTS UTILISES EN TANT QUE VACCINS

IN RODKEY, L., Scott;

SEFERIAN, Peter, G.

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

English

Patent

DT WO 9414469

DS AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK

W: LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA VZ VN AT BE

CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

GA GN ML MR NE SN TD TG

AI WO 1993-US12413 19931220

PRAI US 1992-7/995.373 A 19921223

ICM A61K037-04

ICS A61K039-385; A61K039-39; C07K017-02

L5 ANSWER 26 OF 40 PCTFULL COPYRIGHT 2003 Univentio

AN 1994010294 PCTFULL ED 20020513

TIEN HUMAN MONOCLONAL ANTIBODIES TO HUMAN PARVOVIRUS AND METHODS OF MAKING AND USING THEREOF

TIFR ANTICORPS MONOCLONAUX CONTRE LE PARVOVIRUS CHEZ L'HOMME, PROCEDES D'OBTENTION ET D'UTILISATION

IN ZOLLA-PAZNER, Susan;
ARAKELOV, Serguei;
PA MIROSLAV, Gorny
LA NEW YORK UNIVERSITY
DT English
PI Patent
DS WO 9410294 A1 19940511
W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1993-US10114 A 19931022
PRAI US 1992-7/965,935 19921023
ICM C12N005-22
ICS C12N015-02; A61K039-395; A61K039-42; A61K039-12; G01N033-53

L5 ANSWER 27 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1994009150 PCTFULL ED 20020513
TIEN MONOCLONAL ANTIBODIES TO PROSTATE CELLS
TIFR ANTICORPS MONOCLONAUX CONTRE LES CELLULES DE LA PROSTATE
IN PASTAN, Ira, H.
PA THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES
LA English
DT Patent
PI WO 9409150 A1 19940428
DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1993-US9166 A 19930922
PRAI US 1992-7/958,140 19921008
ICM C12N021-08
ICS C12N005-20; A61K047-48; A61K039-395; G01N033-574; G01N033-577; G01N033-58; A61K049-00; C07K015-00; C12N015-62; C12N001-21

L5 ANSWER 28 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1994008008 PCTFULL ED 20020513
TIEN IMPROVEMENTS IN OR RELATING TO IMMUNE RESPONSE MODIFICATION
TIFR AMELIORATIONS RELATIVES A LA MODIFICATION DE REPONSE IMMUNITAIRE
IN HAWKINS, Robert, Edward;
RUSSELL, Stephen, James;
STEVENSON, Freda, Katherine;
WINTER, Gregory, Paul
PA MEDICAL RESEARCH COUNCIL;
HAWKINS, Robert, Edward;
RUSSELL, Stephen, James;
STEVENSON, Freda, Katherine;
WINTER, Gregory, Paul
LA English
DT Patent
PI WO 9408008 A1 19940414
DS W: AT AU BB BG BR BY CA CH CZ DE DK ES FI GB GR HU JP KP KR KZ LK LU MG MN NW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1993-GB2054 A 19931004
PRAI GB 1992-9220808.1 19921002
ICM C12N015-13
ICS C12N015-62; C12N015-48; C12N015-19; A61K031-70; A61K039-395

L5 ANSWER 29 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1993022349 PCTFULL ED 20020513
TIEN NATURAL HUMAN IGM ANTIBODIES
TIFR ANTICORPS A IGM HUMAINS NATURELS
IN RODMAN, Toby, C.
PA THE INSTITUTE FOR HUMAN GENETICS AND BIOCHEMISTRY;
LA RODMAN, Toby, C.
DT English
PI WO 9322349 A1 19931111

DS W: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN NW NL NO NZ PL RO RU SD SE SK UA US VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
AI WO 1993-US3884 A 19930426
PRAI US 1992-873,917 19920424
US 1992-912,026 19920709
ICM US 1992-924,412 19920730
ICS C07K015-14
GOIN033-68; A61K039-42; A61K039-395

L5 ANSWER 30 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1993012227 PCTFULL ED 20020513
TIEN TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
TIFR ANIMAUX TRANSGENIQUES NON HUMAINS CAPABLES DE PRODUIRE DES ANTICORPS HETEROLOGUES
IN LONBERG, Nils;
PA KAY, Robert, M.
GENPHARM INTERNATIONAL, INC.;
LONBERG, Nils;
KAY, Robert, M.
LA English
DT Patent
PI WO 9312227 A1 19930624
DS W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MN NW NL NO NZ PL RO RU SD SE UA US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR SN TD TG

AI WO 1992-US10983 A 19921217
PRAI US 1991-7/810,279 19911217
US 1992-7/853,408 19920318
US 1992-7/904,068 19920623
ICM C12N015-00

L5 ANSWER 31 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1992017207 PCTFULL ED 20020513
TIEN MONOCLONAL ANTIBODIES WHICH BIND TO SECRETED AND MEMBRANE-BOUND IGE, BUT NOT TO IGE ON BASOPHILS
TIFR ANTICORPS MONOCLONAUX QUI SE LIENT A L'IGE SECRETEE ET LIEE AUX MEMBRANES MAIS QUI NE SE LIENT PAS A L'IGE SE TROUVANT SUR LES LEUCOCYTES BASOPHILES
IN CHANG, Tse, Wen;
DAVIS, Frances, M.;
GOSSETT, Lani, A.;
SUN, Lee, K.;
SUN, Bill, N., C.;
SUN, Cecily, R., Y.;
LIOU, Ruey, S.
TANOX BIOSYSTEMS, INC.;
CHANG, Tse, Wen;
DAVIS, Frances, M.;
GOSSETT, Lani, A.;
SUN, Lee, K.;
SUN, Bill, N., C.;
SUN, Cecily, R., Y.;
LIOU, Ruey, S.
LA English
DT Patent
PI WO 9217207 A1 19921015
DS W: AT AU BB BE BF BG BJ BR CA CF CG CH CM DE DK ES FI FR GA GB GR HU IT JP KP KR LK LU MC MG ML MR NW NL NO RO SD SE SN SU TD TG US

AI WO 1991-US1991 A 19910326
ICM A61K039-40

ICS	A61K039-44	
L5	ANSWER 32 OF 40	PCTFULL COPYRIGHT 2003 Univentio
AN	1992016553	PCTFULL ED 20020513
T1EN	MONOCLONAL AND CHIMERIC ANTIBODIES SPECIFIC FOR HUMAN TUMOR NECROSIS FACTOR	
T1FR	ANTICORPS MONOCLONAUX ET CHIMERES DIRIGES SPECIFIQUEMENT CONTRE LE FACTEUR HUMAIN DE NECROSE DE TUMEURS	
IN	LE. Junming;	
PA	VILCEK, Jan;	
LA	DADDONA, Peter, E.;	
LA	GRAYBEY, John;	
LA	KNIGHT, David, M.;	
PA	SIEGEL, Scott, A.	
LA	NEW YORK UNIVERSITY;	
LA	CENTOCOR, INC.	
LA	English	
PA	Patent	
DS	WO 9216553	A1 19921001
PI	DT	
PI	W:	AT AU BE CA CH DE DK ES FR GB GR IT JP LU MC NL SE
AI	WO 1992-US2190	A 19920318
AI	US 1991-670,827	A 19910318
ICM	C07K0007-00	
ICM	C07K003-18;	C07K015-28;
ICM	A61K039-395;	G01N005-10; C12N015-00; C07H015-12;
ICM	G01N033-53	
L5	ANSWER 33 OF 40	PCTFULL COPYRIGHT 2003 Univentio
AN	1992003918	PCTFULL ED 20020513
T1EN	TRANSGENIC NON-HUMAN ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES	
T1FR	ANIMAUX NON HUMAINS TRANSGENIQUES CAPABLES DE PRODUIRE DES ANTICORPS HETEROLOGUES	
IN	LONBERG, Nils;	
PA	KAY, Robert, M.	
LA	GENPHARM INTERNATIONAL, INC.;	
LA	LONBERG, Nils;	
LA	KAY, Robert, M.	
LA	English	
PA	Patent	
DS	WO 9203918	A1 19920319
PI	W:	AT AU BB BE BF BG BJ BR CA CF CG CH CI CM DE DE DK DK DK ES ES FI FR GA GB GN GR HU IT JP KR KR LU LU MC MC MG MR MW NL NO PL RO SD SE SE SN SU TD TG TG US
AI	WO 1991-US61485	A 19910828
AI	US 1990-574,748	A 19900829
AI	US 1990-575,962	A 19900831
ICM	A01H001-00	
ICM	ICM	
ICM	C07H021-00	
L5	ANSWER 34 OF 40	PCTFULL COPYRIGHT 2003 Univentio
AN	1991018618	PCTFULL ED 20020513
T1EN	IMMUNOTHERAPEUTIC COMPOSITIONS FOR TREATING AND PREVENTING AIDS, ARC AND HIV INFECTION	
T1FR	COMPOSITIONS IMMUNOTHERAPEUTIQUES DE TRAITEMENT ET DE PREVENTION D'INFECTIONS DUES AU SIDA, AU PARA-SIDA ET AU VIH	
IN	FISHER, Richard, A.;	
PA	HESSION, Catherine;	
PA	BURKLY, Linda, C.	
PA	BIODEN, INC.	
LA	English	
LA	Patent	
DS	WO 9118618	A2 19911212
PI	W:	AT AU BE BF BJ CA CF CG CH CI CM DE DK ES FR GA GB GR IT JP LU ML NL SE SN TD TG
AI	WO 1991-US3460	A 19910523

DS W: AT BE CH DE FR GB IT JP KR LU NL SE
AI WO 1989-US5067 A 19891110
PRAI US 1988-289.201 19881223
US 1989-315.736 19890224
ICM A61K000-00

L5 ANSWER 39 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AI 198906138 PCTFULL ED 20020513
TIEN UNIQUE ANTIGENIC EPITOPES ON IGE-BEARING B LYMPHOCYTES
TIFFR EPITOPES ANTIGENIQUES UNIQUES SUR DES LYMPHOCYTES B PORTEURS
D'IMMUNOGLOBULINE E
IN CHANG, Tse-Wen;
SUN, Bill, Nai-Chau;
SUN, Cecily, Rou-Yun
PA TANOX BIOSYSTEMS, INC.
LA English
DT Patent
PI WO 8906138 AI 19890713
DS W: AT AU BE CH DE FR GB IT JP KR LU NL SE SU
AI WO 1988-US4706 A 19881229
PRAI US 1987-140.036 19871231
US 1988-226.421 19880729
US 1988-229.178 19880805
US 1988-272.243 19881116
US 1988-291.068 19881228
ICM A61K039-395
ICS C12P021-00; A61K047-00; C12N005-00; C12N015-00

L5 ANSWER 40 OF 40 PCTFULL COPYRIGHT 2003 Univentio
AN 1985002909 PCTFULL ED 20020507
TIEN ANTI-IDIOYPE ANTIBODIES INDUCED BY SYNTHETIC POLYPEPTIDES
TIFFR ANTICORPS ANTI-IDIOTYPES INDUITS PAR DES POLYPEPTIDES
SYNTHETIQUES
IN CARSON, Dennis, A.;
HOUGHTEN, Richard;
CHEN, Pojen, P.;
VAUGHAN, John, H.;
LERNER, Richard, A.;
FONG, Sherman;
McMILLAN, Seamus, L., H.
PA SCRIPPS CLINIC AND RESEARCH FOUNDATION
LA English
DT Patent
PI WO 8502909 AI 19850704
DS W: AT AU BE CH DE DK FR GB JP KR LU NL SE
AI WO 1984-US2116 A 19841228
PRAI US 1983-566.172 19831228
ICM G01N033-54

=> d ab 36

L5 ANSWER 36 OF 40 PCTFULL COPYRIGHT 2003 Univentio
ABEN Novel oligomeric monoclonal antibodies with high avidity for antigen are described. The oligomers, typically of the IgG class, are secreted having two or more immunoglobulin monomers associated together to form tetraivalent or hexavalent IgG molecules. The oligomers can be formed by substantially duplicating regions of the light chain, particularly the variable region. Oligomeric antibodies of the IgG isotype cross the placenta and can provide passive immunity to a fetus, which is particularly important for protecting newborns against pathogens such as group B streptococci.

ABFR De nouveaux anticorps monoclonaux oligomeres avec une avidite elevee pour des antigenes, typiquement de la classe de IgG, sont secretes avec deux ou plusieurs monomeres associes d'immunoglobuline de facon a former des molecules tetraivalentes ou hexavalentes d'IgG. On peut former les oligomeres en reproduisant essentiellement des regions de la chaine legere, notamment la region variable. Les anticorps oligomeres de l'isotype de l'IgG traversent le placenta et peuvent transmettre une immunité passive a un foetus, ce qui est particulièrement important pour protéger des nouveaux-nés contre des agents pathogenes tels que des streptocoques du groupe B.

=> s bispecific and antibody
L6 11149 BISPECIFIC AND ANTIBODY
-----User Break-----
SEARCH ENDED BY USER
=> s l6 and b(a)cell
2 FILES SEARCHED...
6 FILES SEARCHED...
L7 4150 L6 AND B(A) CELL
=> s l7 and recombinan?
L8 3559 L7 AND RECOMBINAN?
=> dup rem l8
PROCESSING IS APPROXIMATELY 21% COMPLETE FOR L8
PROCESSING IS APPROXIMATELY 41% COMPLETE FOR L8
PROCESSING IS APPROXIMATELY 53% COMPLETE FOR L8
PROCESSING IS APPROXIMATELY 67% COMPLETE FOR L8
PROCESSING IS APPROXIMATELY 77% COMPLETE FOR L8
PROCESSING IS APPROXIMATELY 88% COMPLETE FOR L8
L9 3535 DUP REM L8 (24 DUPLICATES REMOVED)
=> s l9 not yp=>1996
'1996' NOT A VALID FIELD CODE
'1996' NOT A VALID FIELD CODE
'1996' NOT A VALID FIELD CODE
-----User Break-----
SEARCH ENDED BY USER
=> s l9 not py=>1996
'1996' NOT A VALID FIELD CODE
6 FILES SEARCHED...
COMMAND INTERRUPTED
REENTER FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, SCISEARCH, EMBASE, USPATFULL, PCTFULL'
AND TRY AGAIN. OR ENTER '?' FOR MORE INFORMATION.
QUERY PROCESSING INTERRUPTED
The system was temporarily unable to process your query. If this message appears repeatedly, please notify the Help Desk. Enter "HELP STN" for information on contacting the nearest STN Help Desk by telephone or via SEND in the STNMAIL file.
=> d his
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Some commands only work in certain files. For example, the EXPAND

command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE 'MEDLINE, CANCERLIT, BIOSIS, CONFSCI, SCISEARCH, EMBASE, USPATFULL, PCTFULL
' 'MEDLINE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):FILE MEDLINE, CANCERLIT, BIOSIS, CONFSCI, SCISEARCH, EMBASE, USPATFULL, PCTFULL
'FILE' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):quit
'QUIT' IS NOT A VALID FILE NAME
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files that are available. If you have requested multiple files, you can specify a corrected file name or you can enter "IGNORE" to continue accessing the remaining file names entered.
ENTER A FILE NAME OR (IGNORE):end

=> file medline, cancerlit, uspatfull, pctfull, scisearch
COST IN U.S. DOLLARS
FULL ESTIMATED COST

FILE 'MEDLINE' ENTERED AT 12:12:58 ON 03 APR 2003

FILE 'CANCERLIT' ENTERED AT 12:12:58 ON 03 APR 2003

FILE 'USPATFULL' ENTERED AT 12:12:58 ON 03 APR 2003
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'PCTFULL' ENTERED AT 12:12:58 ON 03 APR 2003
COPYRIGHT (C) 2003 Univentio

FILE 'SCISEARCH' ENTERED AT 12:12:58 ON 03 APR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

=> s bispecific and antibody
L10 8995 BISPECIFIC AND ANTIBODY

=> s l10 and b(a)cell
2 FILES SEARCHED...
L11 3932 L10 AND B(A) CELL

=> s l11 not py=>1996
L12 293 L11 NOT PY=>1996

=> s l12 and cytokine
L13 92 L12 AND CYTOKINE

=> d l-92

L13 ANSWER 1 OF 92 MEDLINE

AN 96141137 MEDLINE
DN 96141137 PubMed ID: 8590837
TI Performance of CD3xCD19 bispecific monoclonal antibodies in B cell malignancy.
AU Haagen I A
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO LEUKEMIA AND LYMPHOMA, (1995 Nov) 19 (5-6) 381-93. Ref: 160
Journal code: 9007422. ISSN: 1042-8194.
CY Switzerland
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW, ACADEMIC)
LA English
FS Priority Journals
EM 199604
ED Entered STN: 19960418
Last Updated on STN: 19970203
Entered Medline: 19960404
L13 ANSWER 2 OF 92 MEDLINE
AN 96129473 MEDLINE
DN 96129473 PubMed ID: 8581375
TI T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
AU Belani R; Weiner G J
CS Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.
NC CA55178 (NCI)
SO JOURNAL OF HEMATOLOGY, (1995 Oct) 4 (5) 395-402.
Journal code: 9306048. ISSN: 1061-6128.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199603
ED Entered STN: 19960327
Last Updated on STN: 19970203
Entered Medline: 19960320
L13 ANSWER 3 OF 92 MEDLINE
AN 95354184 MEDLINE
DN 95354184 PubMed ID: 7543021
TI CD8 T cell activation after intravenous administration of CD3 x CD19 bispecific antibody in patients with non-Hodgkin lymphoma.
AU de Gast G C; Haagen I A; van Houten A A; Klein S C; Duits A J; de Weger R A; Vroom T M; Clark M R; Phillips J; van Dijk A J.
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1995 Jun) 40 (6) 390-6.
Journal code: 8605732. ISSN: 0340-7004.
CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
LA English
FS Priority Journals; AIDS
EM 199509
ED Entered STN: 19950921
Last Updated on STN: 19980206
Entered Medline: 19950907
L13 ANSWER 4 OF 92 MEDLINE
AN 95235428 MEDLINE
DN 95235428 PubMed ID: 7719227
TI Bispecific monoclonal antibody therapy of B-cell malignancy.
AU Weiner G J; De Gast G C

CS Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.
SO LEUKEMIA AND LYMPHOMA, (1995 Jan) 16 (3-4) 199-207. Ref: 54
Journal code: 9007422. ISSN: 1042-8194.

CY Switzerland
DT Journal: Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
English, TUTORIAL

LA English
FS Priority Journals
EM 199505
ED Entered STN: 19950605
Last Updated on STN: 19950605
Entered Medline: 19950523

L13 ANSWER 5 OF 92 MEDLINE
AN 94243817 MEDLINE
DN 94243817 PubMed ID: 8187084
TI Role of T-cell subsets in the **bispecific antibody**
(anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
AU Demanet C; Brissinck J; Leo O; Moser W; Thielemans K
CS Laboratory of Physiology, Medical School of the Vrije Universiteit Brussel
(VUB), Belgium.
SO CANCER RESEARCH, (1994 Jun 1) 54 (11) 2973-8.
Journal code: 2984705R. ISSN: 0008-5472.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199406
ED Entered STN: 19940629
Last Updated on STN: 19970203
Entered Medline: 19940621

L13 ANSWER 6 OF 92 MEDLINE
AN 93315244 MEDLINE
DN 93315244 PubMed ID: 7686889
TI CD30-antigen-specific targeting and activation of T cells via murine
bispecific monoclonal antibodies against CD3 and CD28:
Potential use for the treatment of Hodgkin's lymphoma.
CM Erratum in: Int J Cancer 1994 Apr 15;57(2):294
AU Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van
Lier R; Schwonzen M; Diehl V; +
CS Klinik I fur Innere Medizin, Universitat zu Koln, Cologne, Germany.
SO INTERNATIONAL JOURNAL OF CANCER, (1993 Jul 9) 54 (5) 820-7.
Journal code: 0042124. ISSN: 0020-7136.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199308
ED Entered STN: 19930820
Last Updated on STN: 19980206
Entered Medline: 19930812

L13 ANSWER 7 OF 92 CANCERLIT
AN 96141137 CANCERLIT
DN 96141137 PubMed ID: 8590837
TI Performance of CD3xCD19 **bispecific monoclonal antibodies**
in **B cell** malignancy.
AU Haagen I A
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO LEUKEMIA AND LYMPHOMA, (1995 Nov) 19 (5-6) 381-93. Ref: 160
Journal code: 9007422. ISSN: 1042-8194.

CY Switzerland
DT Journal: Article; (JOURNAL ARTICLE)

General Review; (REVIEW)
English, ACADEMIC
FS MEDLINE: Priority Journals
OS MEDLINE 96141137
EM 199604
ED Entered STN: 19960528
Last Updated on STN: 19970509

L13 ANSWER 8 OF 92 CANCERLIT
AN 96129473 CANCERLIT
DN 96129473 PubMed ID: 8581375
TI T cell activation and cytokine production in anti-CD3
bispecific antibody therapy.
AU Belani R; Weiner G J
CS Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.
NC CA55178 (NCI)
SO JOURNAL OF HEMATOLOGY, (1995 Oct) 4 (5) 395-402.
Journal code: 9306048. ISSN: 1061-6128.

CY United States
DT Journal: Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE: Priority Journals
OS MEDLINE 96129473
EM 199603
ED Entered STN: 19960424
Last Updated on STN: 19970509

L13 ANSWER 9 OF 92 CANCERLIT
AN 95354184 CANCERLIT
DN 95354184 PubMed ID: 7543021
TI CD8 T cell activation after intravenous administration of CD3 x CD19
bispecific antibody in patients with non-Hodgkin
lymphoma.
AU de Gast G C; Haagen I A; van Houten A A; Klein S C; Duits A J; de Weger R
A; Vroom T M; Clark M R; Phillips J; van Dijk A J; +
CS Department of Immunology, University Hospital Utrecht, The Netherlands.
SO CANCER IMMUNOLOGY, IMMUNOTHERAPY, (1995 Jun) 40 (6) 390-6.
Journal code: 8605732. ISSN: 0340-7004.

CY GERMANY: Germany, Federal Republic of
DT (CLINICAL TRIAL)
LA English
FS MEDLINE: Priority Journals; AIDS
OS MEDLINE 95354184
EM 199509
ED Entered STN: 19951012
Last Updated on STN: 19960517

L13 ANSWER 10 OF 92 CANCERLIT
AN 95235428 CANCERLIT
DN 95235428 PubMed ID: 7719227
TI **Bispecific monoclonal antibody** therapy of B-
cell malignancy.
AU Weiner G J; De Gast G C
CS Department of Internal Medicine, University of Iowa, Iowa City 52242, USA.
SO LEUKEMIA AND LYMPHOMA, (1995 Jan) 16 (3-4) 199-207. Ref: 54
Journal code: 9007422. ISSN: 1042-8194.

CY Switzerland
DT Journal: Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
English, TUTORIAL
FS MEDLINE: Priority Journals
OS MEDLINE 95235428

EM 199505
ED Entered STN: 19950608
Last Updated on STN: 19950608

L13 ANSWER 11 OF 92 CANCERLIT
AN 94243817 CANCERLIT
DN 94243817 Pubmed ID: 8187084
TI Role of T-cell subsets in the bispecific antibody
DT (anti-idiotype x anti-CD3) treatment of the BCL1 lymphoma.
AU Demaret C; Brissinck J; Leo O; Moser W; Thielemans K
CS Laboratory of Physiology, Medical School of the Vrije Universiteit Brussel
(VUB), Belgium.
SO CANCER RESEARCH, (1994 Jun 1) 54 (11) 2973-8.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 94243817
EM 199406
ED Entered STN: 19941107
Last Updated on STN: 19970509

L13 ANSWER 12 OF 92 CANCERLIT
AN 9315244 CANCERLIT
DN 9315244 Pubmed ID: 7686889
TI CD30-antigen-specific targeting and activation of T cells via murine
bispecific monoclonal antibodies against CD3 and CD28:
potential use for the treatment of Hodgkin's lymphoma.
CM Erratum in: Int J Cancer 1994 Apr 15;57(2):294
AU Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van
Lier R; Schwonzen M; Diehl V; +
CS Klinik I fur Innere Medizin, Universitat zu Koln, Cologne, Germany.
SO INTERNATIONAL JOURNAL OF CANCER, (1993 Jul 9) 54 (5) 820-7.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS MEDLINE; Priority Journals
OS MEDLINE 9315244
EM 199308
ED Entered STN: 19941107
Last Updated on STN: 19960517

L13 ANSWER 13 OF 92 CANCERLIT
AN 92679009 CANCERLIT
DN 92679009
TI FUNCTIONAL STUDIES OF HUMAN ICG FC RECEPTORS.
AU Erbe D V
CS Dartmouth Coll.
SO Diss Abstr Int [B], (1991) 52 (3) 1335.
ISSN: 0419-4217.
(THESIS)
DT English
LA English
FS Institute for Cell and Developmental Biology
EM 199204
ED Entered STN: 19941107
Last Updated on STN: 19941107

L13 ANSWER 14 OF 92 USPATFULL
AN 95:71471 USPATFULL
TI Antibodies to human IL-8 type B receptor
Chuntharapai, Anan, 460 Point San Bruno Blvd., South San Francisco, CA,
United States 94080
Hebert, Caroline, 460 Point San Bruno Blvd., South San Francisco, CA,

United States 94080
Kim, Kyung J., 460 Point San Bruno Blvd., South San Francisco, CA,
United States 94080
Lee, James, 460 Point San Bruno Blvd., South San Francisco, CA, United
States 94080
PI US 5440021 19950808
AI US 1994-202056 19940225 (8)
RLI Continuation-in-part of Ser. No. US 1991-677211, filed on 29 Mar 1991,
now abandoned
DT Utility
FS Granted
LN.CNT 2693
INCL INCLM: 530/388.220
INCLS: 530/388.230; 530/389.100; 530/389.200; 435/240.270
NCL NCLM: 530/388.220
NCLS: 530/388.230; 530/389.100; 530/389.200
IC [6]
ICM: C07K016-28
ICS: C07K016-24; C12N005-22
EXF 424/158.1; 530/388.73; 530/388.23; 530/389.2; 530/388.33; 530/389.1;
435/240.27
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 15 OF 92 USPATFULL
AN 94:60277 USPATFULL
TI Carbohydrate-directed cross-linking reagents
IN Ashkenazi, Avi J., San Mateo, CA, United States
Chamow, Steven M., San Mateo, CA, United States
Kogan, Timothy P., Sugar Land, TX, United States
Genentech, Inc., San Francisco, CA, United States (U.S. corporation)
PA US 5329028 19940712
PI US 1992-926077 19920805 (7)
AI US 1992-926077 19920805 (7)
DT Utility
FS Granted
LN.CNT 1001
INCL INCLM: 548/548.000
INCLS: 548/536.000; 548/547.000; 548/549.000
NCL NCLM: 548/548.000
NCLS: 548/546.000; 548/547.000; 548/549.000
IC [5]
ICM: C07D207-452
EXF 548/546; 548/547; 548/548; 548/549
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 16 OF 92 USPATFULL
AN 93:16591 USPATFULL
TI Hybrid cryptophan aporepressor containing ligand binding sites
IN Lernhardt, Waldemar, Solana Beach, CA, United States
Bourdon, Mario, San Diego, CA, United States
Yoderian, Phil, Ramona, CA, United States
California Institute of Biological Research, La Jolla, CA, United States
(U.S. corporation)
PA US 5190873 19930302
AI US 1991-720222 19910621 (7)
DT Utility
FS Granted
LN.CNT 2112
INCL INCLM: 435/177.000
INCLS: 435/069.700; 435/069.100; 530/350.000; 530/812.000; 930/250.000
NCL NCLM: 435/177.000
NCLS: 435/069.100; 435/069.700; 530/350.000; 530/812.000; 930/250.000
IC [5]
ICM: C07K013-00
ICS: C07K017-00; C07K017-02; C12P021-00
EXF 435/91; 435/69.7; 435/69.1; 435/177; 530/350; 530/812; 930/250

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L13 ANSWER 17 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 18 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 19 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 20 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 21 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 22 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 23 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 24 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 25 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 26 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 27 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 28 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 29 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 30 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 34 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 35 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 36 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 37 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 38 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 39 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 40 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 41 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 42 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 43 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 44 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 45 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 46 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 47 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 48 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 49 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 50 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 51 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 52 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 53 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 54 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 55 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 56 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 57 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 58 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 59 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 60 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 61 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 62 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 63 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 64 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 65 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 66 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 67 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 68 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 69 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 70 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 71 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 72 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 73 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 74 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 75 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 76 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 77 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 78 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 79 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 80 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 81 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 82 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 83 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 84 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 85 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 86 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 87 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 88 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 89 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 90 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 91 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 92 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 93 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 94 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 95 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 96 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 97 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 98 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 99 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 100 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 **** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L13 ANSWER 27 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995033828 PCTFULL ED 20020514
 TIEN MODIFIED CELLS AND METHODS FOR INHIBITING HYPERACUTE REJECTION OF
 XENOGENEIC TRANSPLANTS
 TIFR MODIFICATION CELLULAIRE ET PROCEDES D'INHIBITION DES REACTIONS SURAIGUES
 DE REJET DES XENOGEFFES
 IN EDGE, Albert
 PA DIACRIN, INC.
 LA English
 DT Patent
 PI WO 9533828 A1 19951214
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1995-US5973 A 19950517
 PRAI US 1994-8/253,782
 ICM 19940603
 ICS C12N005-06; C12N005-10; A61K035-407; A61K035-44; A61K038-47

L13 ANSWER 28 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995033823 PCTFULL ED 20020514
 TIEN METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS
 TIFR PROCEDES DE STIMULATION SELECTIVE DE LA PROLIFERATION DES CELLULES T.
 IN JUNE, Carl, H.;
 THOMPSON, Craig, B.;
 NABEL, Gary, J.;
 GRAY, Gary, S.;
 RENNERT, Paul, D.;
 FREEMAN, Gordon, J.
 PA THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY;
 THE REGENTS OF THE UNIVERSITY OF MICHIGAN;
 REFLIGEN CORPORATION;
 DANA-FARBER CANCER INSTITUTE
 LA English
 DT Patent
 PI WO 9533823 A1 19951214
 DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1994-US13782 A 19941201
 PRAI US 1994-8/253,751 19940603
 ICM US 1994-8/253,964 19940603
 ICS C12N005-08
 GOIN033-569; A61K035-14; A61K048-00; C07K016-28; C12N005-20;
 C07K014-705

L13 ANSWER 29 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995033819 PCTFULL ED 20020514
 TIEN CDK4 (CYCLIN DEPENDENT KINASE 4) BINDING PROTEINS
 TIFR PROTEINES SE FIXANT A LA CDK4 (KINASE CYCLINO-DEPENDANTE DE TYPE 4)
 IN DRAETTA, Giulio;
 GYURIS, Jenő
 PA MITOTIX, INC.
 LA English
 DT Patent
 PI WO 9533819 A2 19951214
 DS W: AU CA JP KR AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 AI WO 1995-US7113 A 19950602
 PRAI US 1994-8/253,155 19940602
 ICM C12N015-12
 ICS C07K014-47; C07K016-18; A01K067-027; GOIN033-68; C12Q001-68

L13 ANSWER 30 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 1995033770 PCTFULL ED 20020514
 TIEN LIGANDS FOR INDUCTION OF ANTIGEN SPECIFIC APOPTOSIS IN T CELLS
 TIFR LIGANDS POUR L'INDUCTION D'UNE APOPTOSE SPECIFIQUE A UN ANTIGENE DANS
 LES LYMPHOCYTES T
 IN GRIBBEN, John, G.;

PA	FREEHMAN, Gordon, J.;	LA	REPLIGEN CORPORATION;	LA	ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio	LA	ANSWER 35 OF 92 PCTFULL COPYRIGHT 2003 Univentio
LA	NADLER, Lee, M.;	DT	DANA FARBER CANCER INSTITUTE	DT	1995033052 PCTFULL, ED 20020514	DT	1995027075 PCTFULL ED 20020514
PI	RENNERT, Paul;	PI	Patent	PI	IMMUNOSUPPRESSANT TARGET PROTEINS	PI	1995027075 PCTFULL ED 20020514
DS	JELLIS, Cindy, L.;	DS	English	DS	PROTEINES CIBLES IMMUNODEPRESSIVES	DS	1995027075 PCTFULL ED 20020514
AI	GREENFIELD, Edward;	AI	Gray, Gary, S.	AI	CHI, Marie, Isabel;	AI	1995027075 PCTFULL ED 20020514
PRAI	GRAY, Gary, S.	PRAI	REPLIGEN CORPORATION;	PRAI	COTTAREL, Guillaume;	PRAI	1995027075 PCTFULL ED 20020514
ICM	DANA FARBER CANCER INSTITUTE	ICM	English	ICM	DAMAGNEZ, Veronique	ICM	1995027075 PCTFULL ED 20020514
ICS	Patent	ICS	Patent	ICS	MITOTIX, INC.	ICS	1995027075 PCTFULL ED 20020514
	W: WO 9533770 A1 19951214		W: WO 9533770 A1 19951207		W: WO 9533770 A1 19951207		W: WO 9533770 A1 19951207
	US 1994-8/253,783 A 19950602		US 1994-8/253,783 A 19950602		US 1994-8/253,783 A 19950602		US 1994-8/253,783 A 19950602
	C07K014-705		C07K014-705		C07K014-705		C07K014-705
	C07K016-28; A61K039-395; A61K038-17		C07K016-28; A61K039-395; A61K038-17		C07K016-28; A61K039-395; A61K038-17		C07K016-28; A61K039-395; A61K038-17
L13	ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 31 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	1995033052 PCTFULL, ED 20020514	AN	1995033052 PCTFULL, ED 20020514	AN	1995033052 PCTFULL, ED 20020514	AN	1995033052 PCTFULL, ED 20020514
TIEN	IMMUNOSUPPRESSANT TARGET PROTEINS	TIEN	IMMUNOSUPPRESSANT TARGET PROTEINS	TIEN	IMMUNOSUPPRESSANT TARGET PROTEINS	TIEN	IMMUNOSUPPRESSANT TARGET PROTEINS
IN	PROTEINES CIBLES IMMUNODEPRESSIVES	IN	PROTEINES CIBLES IMMUNODEPRESSIVES	IN	PROTEINES CIBLES IMMUNODEPRESSIVES	IN	PROTEINES CIBLES IMMUNODEPRESSIVES
	BERLIN, Vivian;		BERLIN, Vivian;		BERLIN, Vivian;		BERLIN, Vivian;
PA	CHI, Marie, Isabel;	PA	CHI, Marie, Isabel;	PA	CHI, Marie, Isabel;	PA	CHI, Marie, Isabel;
LA	COTTAREL, Guillaume;	LA	COTTAREL, Guillaume;	LA	COTTAREL, Guillaume;	LA	COTTAREL, Guillaume;
DT	DAMAGNEZ, Veronique	DT	DAMAGNEZ, Veronique	DT	DAMAGNEZ, Veronique	DT	DAMAGNEZ, Veronique
PI	MITOTIX, INC.	PI	MITOTIX, INC.	PI	MITOTIX, INC.	PI	MITOTIX, INC.
DS	English	DS	English	DS	English	DS	English
AI	W: WO 9533770 A1 19951207	AI	W: WO 9533770 A1 19951207	AI	W: WO 9533770 A1 19951207	AI	W: WO 9533770 A1 19951207
PRAI	US 1994-8/253,783 A 19950602	PRAI	US 1994-8/253,783 A 19950602	PRAI	US 1994-8/253,783 A 19950602	PRAI	US 1994-8/253,783 A 19950602
ICM	US 1994-8/360,144 19941220	ICM	US 1994-8/360,144 19941220	ICM	US 1994-8/360,144 19941220	ICM	US 1994-8/360,144 19941220
ICS	C12N015-31; C12N015-62; C12N015-81; C12N001-19; C07K014-47;	ICS	C12N015-31; C12N015-62; C12N015-81; C12N001-19; C07K014-47;	ICS	C12N015-31; C12N015-62; C12N015-81; C12N001-19; C07K014-47;	ICS	C12N015-31; C12N015-62; C12N015-81; C12N001-19; C07K014-47;
	C07K014-40; C07K016-18; C12Q001-68; G01N033-53		C07K014-40; C07K016-18; C12Q001-68; G01N033-53		C07K014-40; C07K016-18; C12Q001-68; G01N033-53		C07K014-40; C07K016-18; C12Q001-68; G01N033-53
L13	ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 32 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	1995030015 PCTFULL, ED 20020514	AN	1995030015 PCTFULL, ED 20020514	AN	1995030015 PCTFULL, ED 20020514	AN	1995030015 PCTFULL, ED 20020514
TIEN	ISOLATED EPSTEIN-BARR VIRUS BZLF2 PROTEINS THAT BIND MHC CLASS II BETA CHAINS	TIEN	ISOLATED EPSTEIN-BARR VIRUS BZLF2 PROTEINS THAT BIND MHC CLASS II BETA CHAINS	TIEN	ISOLATED EPSTEIN-BARR VIRUS BZLF2 PROTEINS THAT BIND MHC CLASS II BETA CHAINS	TIEN	ISOLATED EPSTEIN-BARR VIRUS BZLF2 PROTEINS THAT BIND MHC CLASS II BETA CHAINS
TIFR	'beta' DU COMPLEXE MAJEUR D'HISTOCOMPATIBILITE DE CLASSE II	TIFR	'beta' DU COMPLEXE MAJEUR D'HISTOCOMPATIBILITE DE CLASSE II	TIFR	'beta' DU COMPLEXE MAJEUR D'HISTOCOMPATIBILITE DE CLASSE II	TIFR	'beta' DU COMPLEXE MAJEUR D'HISTOCOMPATIBILITE DE CLASSE II
IN	ALDERSON, Mark;	IN	ALDERSON, Mark;	IN	ALDERSON, Mark;	IN	ALDERSON, Mark;
	ARMITAGE, Richard, J.;		ARMITAGE, Richard, J.;		ARMITAGE, Richard, J.;		ARMITAGE, Richard, J.;
PA	COHEN, Jeffrey, I.;	PA	COHEN, Jeffrey, I.;	PA	COHEN, Jeffrey, I.;	PA	COHEN, Jeffrey, I.;
LA	COME, Michael, R.;	LA	COME, Michael, R.;	LA	COME, Michael, R.;	LA	COME, Michael, R.;
DT	FAREAH, Theresa, M.;	DT	FAREAH, Theresa, M.;	DT	FAREAH, Theresa, M.;	DT	FAREAH, Theresa, M.;
PI	HUTT-FLETCHER, Lindsey, M.;	PI	HUTT-FLETCHER, Lindsey, M.;	PI	HUTT-FLETCHER, Lindsey, M.;	PI	HUTT-FLETCHER, Lindsey, M.;
DS	SPRIGGS, Melanie, K.	DS	SPRIGGS, Melanie, K.	DS	SPRIGGS, Melanie, K.	DS	SPRIGGS, Melanie, K.
	IMMUNEX CORPORATION;		IMMUNEX CORPORATION;		IMMUNEX CORPORATION;		IMMUNEX CORPORATION;
PA	THE CURATORS OF THE UNIVERSITY OF MISSOURI;	PA	THE CURATORS OF THE UNIVERSITY OF MISSOURI;	PA	THE CURATORS OF THE UNIVERSITY OF MISSOURI;	PA	THE CURATORS OF THE UNIVERSITY OF MISSOURI;
LA	NATIONAL INSTITUTES OF HEALTH	LA	NATIONAL INSTITUTES OF HEALTH	LA	NATIONAL INSTITUTES OF HEALTH	LA	NATIONAL INSTITUTES OF HEALTH
DT	English	DT	English	DT	English	DT	English
PI	W: WO 9530015 A2 19951109	PI	W: WO 9530015 A2 19951109	PI	W: WO 9530015 A2 19951109	PI	W: WO 9530015 A2 19951109
DS	US 1994-8/235,397 A 19950428	DS	US 1994-8/235,397 A 19950428	DS	US 1994-8/235,397 A 19950428	DS	US 1994-8/235,397 A 19950428
AI	C12N015-62	AI	C12N015-62	AI	C12N015-62	AI	C12N015-62
PRAI	C07K014-05; A61K039-245; C07K016-00	PRAI	C07K014-05; A61K039-245; C07K016-00	PRAI	C07K014-05; A61K039-245; C07K016-00	PRAI	C07K014-05; A61K039-245; C07K016-00
ICM		ICM		ICM		ICM	
ICS		ICS		ICS		ICS	
L13	ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio	L13	ANSWER 33 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN	1995028957 PCTFULL, ED 20020514	AN	1995028957 PCTFULL, ED 20020514	AN	1995028957 PCTFULL, ED 20020514	AN	1995028957 PCTFULL, ED 20020514

JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT
RO RU SD SE SG SI SK TJ TT UA UG US UZ VN KE MW SD SZ UG AT
BE CH DE FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI
CM GA GN ML MR NE SN TD TG
WO 1995-US4024 A 19950330
US 1994-8/221,821
C12P021-08
C07K016-18: C12N005-10; C07K014-47; G01N033-577; A61K039-395;
A61K047-48

L13 AN ANSWER 39 OF 92 PCTFULL COPYRIGHT 2003 Univentio
1995024217 PCTFULL ED 20020514
T1EN METHODS FOR MODULATING T CELL UNRESPONSIVENESS
T1FR PROCESSES DE MODULATION DE L'ENERGIE DES CELLULES T
IN BOUSSIOTIS, Vassiliki, A.;
FREEMAN, Gordon, J.;
NADLER, Lee, M.;
DANA-FARBER CANCER INSTITUTE;
BOUSSIOTIS, Vassiliki, A.;
FREEMAN, Gordon, J.;
NADLER, Lee, M.
English
Patent
PI WO 9524217 A1 19950914
DS W: AU CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US2916 A 19950308
PRAI US 1994-8/207,932
ICM A61K039-395
ICS C12N005-00; C12N005-10

WO 9527042 A1 19951012
W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
WO 1995-US4060 A 19950330
US 1994-8/221,404
C12N005-10
A61K035-34; A61K048-00

L13 AN ANSWER 40 OF 92 PCTFULL COPYRIGHT 2003 Univentio
1995023865 PCTFULL ED 20020514
T1EN ANTI-IL-8 MONOCLONAL ANTIBODIES FOR TREATMENT OF INFLAMMATORY
DISORDERS
T1FR ANTICORPS MONOCLONAUX ANTI-IL-8 POUR LE TRAITEMENT DES TROUBLES
IN DOERSCHUK, Claire, M.;
FONG, Sherman;
HERBERT, Caroline, Alice;
KIM, Kyung, Jin;
LEONG, Steven, R.
GENENTECH, INC.;
INDIANA UNIVERSITY FOUNDATION
English
Patent
PI WO 9523865 A1 19950908
DS W: CA JP MX AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US2589 A 19950301
PRAI US 1994-8/205,864
ICM C12N015-70
ICS C07K016-24; C12N015-13; C12P021-08; A61K039-395

ANSWER 37 OF 92 PCTFULL COPYRIGHT 2003 Univentio
1995026740 PCTFULL ED 20020514
T1EN IMPROVED METHODS FOR TRANSPLANTATION USING MODIFIED CELLS AND T CELL
INHIBITORY AGENTS
T1FR PROCESSES AMELIORES DE TRANSPLANTATION A L'AIDE DE CELLULES MODIFIEES ET
D'AGENTS INHIBITEURS DE LYMPHOCYTES T
IN FRASER, Thomas
DIACKIN, INC.
English
Patent
PI WO 9526740 A1 19951012
DS W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US3959 A 19950330
PRAI US 1994-8/220,724
ICM A61K035-39
ICS A61K038-13; A61K035-39; A61K035-39; A61K031-445;
A61K035-39; A61K031-52; A61K035-39; A61K031-57; A61K035-39;
A61K031-675

ANSWER 38 OF 92 PCTFULL COPYRIGHT 2003 Univentio
1995024417 PCTFULL ED 20020514
T1EN NUCLEOTIDE OR NUCLEOSIDE PHOTOAFFINITY COMPOUND MODIFIED
ANTICORPES MODIFIES PAR DES COMPOSES DE PHOTOAFFINITE NUCLEOTIDIQUES OU
NUCLEOSIDIQUES, LEURS PROCESSES DE FABRICATION ET D'UTILISATION
IN HALEY, Boyd, E.;
KOHLEH, Heinz;
RAJAGOPALAN, Krishnan;
PAVLINKOVA, Gabriela
THE UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
English
Patent
PI WO 9524417 A1 19950914
DS W: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1995-US3160 A 19950313
PRAI US 1994-8/208,822
ICM C07K001-13
ICS C07K001-107; C07K016-00; C07K017-00; C12Q001-25; G01N033-53

ANSWER 41 OF 92 PCTFULL COPYRIGHT 2003 Univentio
1995021618 PCTFULL ED 20020514
T1EN IMMUNOMODULATION USING NKR-P1, CD69 AND LIGANDS THEREFOR
T1FR IMMUNOMODULATION A L'AIDE DE NKR-P1 ET DE CD69 ET LIGANDS UTILISES
IN FEIZI, Ten;
BEZOUS?KA, Karel
MEDICAL RESEARCH COUNCIL;
FEIZI, Ten;
BEZOUS?KA, Karel
English
Patent
PI WO 9521618 A1 19950817
DS W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP
KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NL NO NZ PL PT
RO RU SD SE SI SK TJ TT UA UG US UZ VN KE MW SD SZ UG AT BE
CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
CA GN ML MR NE SN TD TG
WO 1995-GB321 A 19950215
GB 1994-9402890.9 19940215
GB 1994-9412952.5 19940628
GB 1994-9422584.4 19941109
A61K031-70
A61K031-725; A61K031-715

L13 ANSWER 42 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195020655 PCTFULL ED 20020514
 TIEN NOVEL CELL SURFACE RECEPTOR, ANTIBODY COMPOSITIONS, AND
 TIFR METHODS OF USING SAME
 IN NOUVEAU RECEPTEUR DE SURFACE CELLULAIRE, COMPOSITIONS D'ANTICORPS ET
 IN PROCÉDES UTILISANT UN TEL RECEPTEUR
 PA ALTIERI, Dario C.
 LA THE SCRIPPS RESEARCH INSTITUTE
 DT Patent
 PI Patent
 DS WO 9520655 AU CA FI JP NO AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
 W: SE
 A1 19950803
 A1 WO 1995-US666 A 19950118
 PRAI US 1994-8/189,309 19940128
 ICM C12N015-12
 ICS C07K014-705; C07K016-28; A61K039-395; C01N033-577; G01N033-68
 L13 ANSWER 43 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195019181 PCTFULL ED 20020514
 TIEN A METHOD OF TREATMENT OF PARASITIC INFECTION USING IGE ANTAGONISTS
 TIFR PROCÉDE DE TRAITEMENT DE LA PARASITOSE A L'AIDE D'ANTAGONISTES DE L'IGE
 IN AMIRI, Payman;
 HAAK-FREDSCHO, Mary;
 JARDIEU, Paula, M.
 PA GENENTECH, INC.
 LA English
 DT Patent
 PI Patent
 DS WO 9519181 JP MX KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL
 W: PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
 A1 19950720
 A1 WO 1995-US87 A 19950105
 PRAI US 1994-8/184,083 19940118
 ICM A61K039-395
 ICS A61K038-17
 L13 ANSWER 44 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195018974 PCTFULL ED 20020514
 TIEN UBIQUITIN CONJUGATING ENZYMES
 TIFR ENZYMES CONJUGUANT L'UBIQUITINE
 IN DRAETTA, Giulio;
 ROLFE, Mark;
 ECKSTEIN, Jens, W.;
 COTTAREL, Guillaume;
 GYURIS, Jenő
 PA MITOTIX, INC.
 LA English
 DT Patent
 PI Patent
 DS WO 9518974 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: A2 19950713
 A1 19950104
 PRAI US 1994-8/176,937 19940104
 US 1994-8/247,904 19940523
 US 1994-8/250,795 19940527
 US 1994-8/305,520 19940913
 ICM G01N033-68
 ICS C120001-00; G01N033-58; C120001-04; G01N033-50; C12N009-00;
 C07K016-40; C12N015-52; C12N015-62; C12N005-10; A01K067-027;
 C12Q001-68
 L13 ANSWER 45 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195018858 PCTFULL ED 20020514
 TIEN THROMBOPOIETIN
 TIFR THROMBOPOIETINE
 IN EATON, Dan, L.;

DE SAUVAGE, Frederic, J.
 GENENTECH, INC.;
 EATON, Dan, L.;
 DE SAUVAGE, Frederic, J.
 English
 Patent
 PI Patent
 DS WO 9518858 AU CA FI JP NO AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: A2 19950713
 A1 19950104
 PRAI US 1994-8/176,553 19940103
 ICM US 1994-8/185,607 19940121
 ICS US 1994-8/196,689 19940215
 US 1994-8/223,283 19940404
 US 1994-8/249,376 19940525
 US 1994-8/348,657 19941202
 US 1994-8/348,658 19941202
 C12N015-19
 C07K014-52; C07K016-24; A61K038-19
 L13 ANSWER 46 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195016036 PCTFULL ED 20020514
 TIEN IFN- γ RECEPTOR 'beta'-CHAIN AND DERIVATIVES THEREOF
 TIFR CHAÎNE 'beta' DE RECEPTEURS D'IFN- γ 'gamma' ET LEURS DERIVÉS
 IN AGUET, Michel;
 Boehni, Ruth;
 HENMI, Silvio
 PA AGUET, Michel;
 Boehni, Ruth;
 Boehni, Silvio
 LA English
 DT Patent
 PI Patent
 DS WO 9516036 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: A2 19950615
 A1 19941207
 PRAI US 1993-8/164,596 19931209
 ICM C12N015-12
 ICS C07K014-715; C12N015-62; C07K016-28; C12N005-10; A61K038-17;
 A61K039-395; C12Q001-68
 L13 ANSWER 47 OF 92 PCTFULL COPYRIGHT 2003 Univentio
 AN 195015979 PCTFULL ED 20020514
 TIEN PRETARGETING METHODS AND COMPOUNDS
 TIFR PROCÉDES ET COMPOSÉS DE PRECIBLAGE
 IN THEODORE, Louis, J.;
 MEYER, Damon, L.;
 MALLET, Robert, W.;
 KASINA, Sudhakar;
 RENO, John, M.;
 AXWORTHY, Donald, B.;
 GUSTAVSON, Linda, M.
 PA NEORX CORPORATION
 LA English
 DT Patent
 DS WO 9515979 AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
 W: A1 19950615
 A1 19941207
 PRAI US 1994-US14174 19941207
 ICM US 1993-8/163,188 19931207
 ICS C07K014-52
 C07K014-525; C07K014-53; C07K014-535; C07K014-54; C07K014-555;
 C07K016-00; C07K016-30; A61K038-17; A61K038-38; A61K051-10

L13 ANSWER 48 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 195015976 PCTFULL ED 20020514
TIEN NUCLEIC ACIDS ENCODING A HOUSE DUST MITE ALLERGEN, DER P III, AND USES THEREFOR
TIFR ACIDES NUCLEOTIQUES CODANT UN ALLERGENE D'ACARIENS DE LA POUSSIERE DE MAISON, DER P III, ET UTILISATION DE CES ACIDES
IN THOMAS, Wayne, R.;
CHUA, Kaw-Yan;
ROGERS, Bruce, L.;
KUO, Mei-Chang
PA IMMUNOLOGIC PHARMACEUTICAL CORPORATION;
INSTITUTE FOR CHILD HEALTH RESEARCH
LA English
DT Patent
PI Patent
DS WO 9515976 A1 19950615
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
AI WO 1994-US14073 A 19941207
PRAI US 1993-8/163,919
ICM C07K014-435
L13 ANSWER 49 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 195015341 PCTFULL ED 20020514
TIEN ANTIBODY AGAINST CARCINOEMBRYONIC ANTIGEN (CEA)
TIFR ANTICORPS DIRIGE CONTRE L'ANTIGENE CARCINO-EMBRYONNAIRE (CEA)
IN CHESTER, Kerry, Anne;
HAWKINS, Robert, Edward;
BEGENT, Richard, Henry, John
PA CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED;
CHESTER, Kerry, Anne;
HAWKINS, Robert, Edward;
BEGENT, Richard, Henry, John
LA English
DT Patent
PI Patent
DS WO 9515341 A1 19950608
W: AU CA HU JP KR NZ US AT BE CH DE DK ES FR GR IE IT LU MC NL PT SE
AI WO 1994-GB2658 A 19941205
PRAI GB 1993-9324807.8
ICM C07K016-30
ICS A61K039-395; A61K047-48; A61K051-10; C07K016-00; C12N015-13; C12N015-63
L13 ANSWER 50 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 195015084 PCTFULL ED 20020514
TIEN NOVEL APOPTOSIS-MODULATING PROTEINS, DNA ENCODING THE PROTEINS AND METHODS OF USE THEREOF
TIFR NOUVELLES PROTEINES MODULANT L'APOPTOSE, ADN CODANT POUR CES PROTEINES, ET LEUR MODE D'UTILISATION
IN BARR, Philip, J.;
KIEFER, Michael, C.;
PA LXR BIOTECHNOLOGY INC.;
KIEFER, Michael, C.;
BARR, Philip, J.
LA English
DT Patent
PI Patent
DS WO 9515084 A1 19950608
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AI WO 1994-US13930 A 19941130
PRAI US 1993-8/160,067
ICM US 1994-8/320,157
ICS A01N043-04
A01N063-00; A61K031-70; A61K037-00; C07K016-00; C07K016-18; C12N001-08; C12N001-21; C12N005-00; C12N005-06; C12N005-16; C12N007-00; C12N015-09; C12N015-13
L13 ANSWER 51 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 195013095 PCTFULL ED 20020514
TIEN THERAPY
TIFR THERAPIE
IN SMITH, Gary, Keith;
BLUMENKOPF, Todd, Andrew;
CORY, Michael
PA THE WELLCOME FOUNDATION LIMITED;
SMITH, Gary, Keith;
BLUMENKOPF, Todd, Andrew;
CORY, Michael
LA English
DT Patent
PI Patent
DS WO 9513095 A2 19950518
W: AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ TT UA UZ VN KE MW SD SZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG
AI WO 1994-GB2483 A 19941111
PRAI GB 1993-9323429.2
ICM A61K047-48
ICS C12N009-64; C12N015-52; C12N015-63; C12N005-10
L13 ANSWER 52 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 195003408 PCTFULL ED 20020514
TIEN B7-2; CTLA4/CD.28 COUNTER RECEPTOR
TIFR B7-2; CONTRRE-RECEPTEUR DE CTLA4/CD28
IN FREEMAN, Gordon, J.;
NADLER, Lee, M.;
GRAY, Gary, S.;
GREENFIELD, Edward
PA DANA-FARBER CANCER INSTITUTE;
REPLIGEN CORPORATION
LA English
DT Patent
PI Patent
DS WO 9503408 A1 19950202
W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1994-US8423 A 19940726
PRAI US 1993-8/101,624
ICS US 1993-8/109,393
US 1993-8/147,773
C12N015-12
C07K014-705; C07K016-28; C12N005-10; C12N015-62; A61K035-12; A61K038-17; A01K067-027; G01N033-68
L13 ANSWER 53 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 194029436 PCTFULL ED 20020513
TIEN METHODS FOR SELECTIVELY STIMULATING PROLIFERATION OF T CELLS
TIFR PROCESSES DE STIMULATION SELECTIVE DE LA PROLIFERATION DES LYMPHOCYTES T
IN JUNE, Carl, H.;
THOMPSON, Craig, B.;
NABEL, Gary, J.;
GRAY, Gary, S.;
RENNERT, Paul, D.
PA THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY; THE REGENTS OF THE UNIVERSITY OF MICHIGAN;

LA	REPLIGEN CORPORATION	TJ	TT	UA	US	UZ	VN	AT	BE	CH	DE	DK	ES	FR	GB	GR	IE	IT	LU	MC
DT	English	NL	PT	SE	BF	BJ	CF	CI	CM	GA	GN	ML	MR	NE	SN	TD	TD	TD	TD	TD
PI	Patent																			
DS	WO 9429436	AI	19941222																	
AI	W:	WO 1994-US6255	AU	CA	JP	AT	BE	CH	DE	DK	ES	FR	GB	GR	IE	IT	LU	MC	NL	PT
PRAI	US 1993-8/073,223	A	19940603																	
ICM	C12N005-08																			
ICS	A61K035-14; C12N005-20; C12P021-08; A61K037-02																			
L13	ANSWER 54 OF 92	PCTFULL	COPYRIGHT 2003	Univentio																
AN	1994025047	PCTFULL	ED 20020513																	
TIER	INHIBITION OF LEUKOCYTE ADHESION																			
TIFR	INHIBITION DE L'ADHESION DES LEUCOCYTES																			
IN	LASKY, Laurence, A.;																			
	BAUMHUETER, Susanne;																			
	ROSEN, Steven, D.;																			
PA	SINGER, Mark, S.;																			
	GENENTECH, INC.;																			
	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA;																			
	LASKY, Laurence, A.;																			
	BAUMHUETER, Susanne;																			
	ROSEN, Steven, D.;																			
	SINGER, Mark, S.;																			
LA	English																			
DT	Patent																			
PI	WO 9425047	AI	19941110																	
DS	W:	WO 1994-US3791	AU	CA	JP	US	AT	BE	CH	DE	DK	ES	FR	GB	GR	IE	IT	LU	MC	NL
AI	US 1993-8/056,454	A	19940406																	
PRAI	A61K037-02																			
ICM	A61K039-395; C07K015-00																			
ICS																				
L13	ANSWER 55 OF 92	PCTFULL	COPYRIGHT 2003	Univentio																
AN	1994023760	PCTFULL	ED 20020513																	
TIER	TRANSGENIC ANIMAL MODEL FOR AUTOIMMUNE DISEASES																			
TIFR	MODELE D'ANIMAL TRANSGENIQUE POUR MALADIES AUTOIMMUNES																			
IN	HARLAN, David, M.;																			
	JUNE, Carl, H.;																			
PA	THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE NAVY																			
LA	English																			
DT	Patent																			
PI	WO 9423760	AI	19941027																	
DS	W:	WO 1994-US1674	AU	CA	JP	AT	BE	CH	DE	DK	ES	FR	GB	GR	IE	IT	LU	MC	NL	PT
AI	US 1993-8/048,042	A	19940217																	
PRAI	A61K067-00																			
ICM	A61K049-00; C07H017-00; C12N005-00; C12N015-00; G01N031-00;																			
ICS	G01N033-48																			
L13	ANSWER 56 OF 92	PCTFULL	COPYRIGHT 2003	Univentio																
AN	1994020614	PCTFULL	ED 20020513																	
TIER	ALLERGENIC PROTEIN AND PEPTIDES FROM HOUSE DUST MITE AND USES THEREFOR																			
TIFR	PROTEINE ET PEPTIDES ALLERGENES OBTENUS A PARTIR D'ACARIENS DETRITICOLES																			
IN	ET LEURS UTILISATIONS																			
	THOMAS, Wayne, Robert;																			
PA	CHUA, Kaw-Yan																			
	INSTITUTE FOR CHILD HEALTH RESEARCH;																			
	THOMAS, Wayne, Robert;																			
	CHUA, Kaw-Yan																			
LA	English																			
DT	Patent																			
PI	WO 9420614	AI	19940915																	
DS	W:	AT	AU	BB	BG	BR	BY	CA	CH	CN	CZ	DE	DK	ES	FI	GB	HU	JP	KG	KP
		KR	KZ	LK	LV	LU	MD	MG	MN	NL	NO	NZ	PL	PT	RO	RU	SD	SE	SI	SK

LA	AI	WO 1993-GB2492	A	19931203
DT	PRAI	GB 1992-9225453.1		19921204
PI		GB 1993-9300816.7		19930116
DS		GB 1993-93303614.7		19930510
		GB 1993-9319969.3		19930922
	ICM	CI2N015-13		
	ICS	C07K015-28; C12P021-08; C12N015-62; C12N015-70; C07K001-00		
AI	L13	ANSWER 62 OF 92	PCTFULL	COPYRIGHT 2003 Univentio
PRAI	AN	1994010308	PCTFULL	ED 20020513
ICM	TIEN	METHODS OF PREPARING SOLUBLE, OLIGOMERIC PROTEINS		
ICS	IN	PROCEDE DE PREPARATION DE PROTEINES OLIGOMERES SOLUBLES		
		SRINIVASAN, Subhashini		
	PA	IMMUNEX CORPORATION		
	LA	English		
	DT	Patent		
	PI	WO 9410308	AI	19940511
	DS	W: AU CA JP NZ AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
	AI	WO 1993-US10034	A	19931020
	PRAI	US 1992-77969.703		19921023
		US 1993-8/107.353		19930813
	ICM	CI2N015-12		
	ICS	CI2N015-62		
L13	ANSWER 63 OF 92	PCTFULL	COPYRIGHT 2003 Univentio	
AN	AN	1994009363	PCTFULL	ED 20020513
TIEN	TIEN	CANCER DIAGNOSIS AND THERAPY		
TIFR	TIFR	DIAGNOSTIC ET THERAPIE CONTRE LE CANCER		
IN	IN	UHR, Jonathan, W.;		
		VITETTA, Ellen, S.;		
	PA	SCHUEERMANN, Richard, H.		
	LA	BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM		
	DT	English		
	PI	WO 9409363	AI	19940428
	DS	W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
	AI	WO 1993-US9841	A	19931014
	PRAI	US 1992-7/967.072		19921014
	ICM	G01N033-48		
	ICS	G01N033-533; G01N033-536; G01N021-53; G01N021-21; G01N021-64		
L13	ANSWER 64 OF 92	PCTFULL	COPYRIGHT 2003 Univentio	
AN	AN	1994009137	PCTFULL	ED 20020513
TIEN	TIEN	ANTIBODIES AGAINST TYPE 2 TUMOR NECROSIS FACTOR RECEPTOR		
TIFR	TIFR	ANTICORPS CONTRE LE RECEPTEUR DU FACTEUR DE NECROSE DE TUMEURS DE TYPE 2		
IN	IN	FENDLY, Brian;		
		GOEDDEL, David, V.;		
	PA	PALLADINO, Michael, A.;		
	LA	TARTAGLIA, Louis, A.		
	DT	English		
	PI	WO 9409137	AI	19940428
	DS	W: CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE		
	AI	WO 1993-US9620	A	19931008
	PRAI	US 1992-7/961.602		19921015
	ICM	CI2N015-13		
	ICS	CI2P021-08; C12N005-20; A61K039-395; A61K048-00; C12N005-08; A61K035-14; G01N033-577; G01N033-68		
L13	ANSWER 65 OF 92	PCTFULL	COPYRIGHT 2003 Univentio	
AN	AN	1994009117	PCTFULL	ED 20020513
TIEN	TIEN	DIRECT SELECTION OF CELLS BY SECRETION PRODUCT		

TIFR IN SELECTION DIRECTE DE CELLULES PAR UN PRODUIT DE SECRETION
MILTENYI, Stefan;
RADBRUCH, Andreas;
MANZ, Rudi
PA MILTENYI BIOTEC, INC.;
MILTENYI, Stefan;
RADBRUCH, Andreas;
MANZ, Rudi
LA English
DT Patent
PI WO 9409117 A1 19940428
DS AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK
LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE
CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM
CA GN ML MR NE SN TD TG
AI WO 1993-US10126 A 19931021
PRAI US 1992-7/965,934 A 19921021
ICM C12N005-00
ICS A01N001-02; G01N033-536; G01N033-58; G01N033-566; G01N033-53;
G01N033-563; C12Q001-00; C12Q001-02

L13 ANSWER 66 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994008038 PCTFULL ED 20020513
TIEN BISPECIFIC REAGENTS FOR REDIRECTED TARGETING OF LOW DENSITY
LIPOPROTEIN
TIFR AGENTS BISPECIFIQUES DE REORIENTATION DU CIBLAGE DES LIPOPROTEINES DE
FAIBLE DENSITE
IN FANGER, Michael, W.;
MORGANELLI, Peter, M.
PA TRUSTEES OF DARTMOUTH COLLEGE
LA English
DT Patent
PI WO 9408038 A1 19940414
DS AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: WO 1993-US9556 A 19931004
PRAI US 1992-7/955,681 A 19921002
ICM C12P021-08
ICS C12N005-08; A61K039-395; A61K037-02; G01N033-577; G01N033-92

L13 ANSWER 67 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994006920 PCTFULL ED 20020513
TIEN RECOMBINANT VIRUSES DISPLAYING A NONVIRAL POLYPEPTIDE ON THEIR EXTERNAL
SURFACE
TIFR VIRUS RECOMBINES PRESENTANT UN POLYPEPTIDE NON-VIRAL SUR LEUR SURFACE
EXTERNE
IN RUSSELL, Stephen, James;
HAWKINS, Robert, Edward;
WINTER, Gregory, Paul
PA MEDICAL RESEARCH COUNCIL;
RUSSELL, Stephen, James;
HAWKINS, Robert, Edward;
WINTER, Gregory, Paul
LA English
DT Patent
PI WO 9406920 A1 19940331
DS AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK
LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN AT BE CH
DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA
GN ML MR NE SN TD TG
AI WO 1993-GB1992 A 19930922
PRAI GB 1992-9220010.4 A 19920922
ICM GB 1993-9304962.5 19930311
ICS A61K048-00; C12N015-10; C12N015-87; C12N015-62

L13 ANSWER 68 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994005691 PCTFULL ED 20020513
TIEN CD27 LIGAND
TIFR BECKMANN, M., Patricia;
GOODWIN, Raymond, G.;
GIRI, Judith, G.;
ARMITAGE, Richard, J.
PA IMMUNEX CORPORATION
LA English
DT Patent
PI WO 9405691 A1 19940317
DS AU CA FI JP KR NO NZ AT BE CH DE DK ES FR GB GR IE IT LU MC
NL PT SE A 19930901
AI WO 1993-US8223 A 19920908
PRAI US 1992-7/941,648 A 19930813
ICM US 1993-8/106,507
ICS C07H021-04
C07K013-00; C07K015-28; C12P021-06; C12N015-00

L13 ANSWER 69 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1994004690 PCTFULL ED 20020513
TIEN BISPECIFIC IMMUNOADHESINS
TIFR IMMUNOADHESINES BISPECIFIQUES
IN ASHKENAZI, Avi, J.;
CHAMOW, Steven, M.
PA GENENTECH, INC.
LA English
DT Patent
PI WO 9404690 A1 19940303
DS AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
W: WO 1993-US7783 A 19930817
PRAI US 1992-7/931,811 A 19920817
ICM C12N015-62
ICS C12N015-13; C12N015-12; C07K015-28

L13 ANSWER 70 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993025218 PCTFULL ED 20020513
TIEN METHODS AND COMPOSITIONS FOR INHIBITING ENDOTHELIAL CELL AND FIBRINOGEN
MEDIATED INFLAMMATION
TIFR PROCESSES ET COMPOSITIONS D'INHIBITION D'INFLAMMATIONS PROVOQUEES PAR DES
CELLULES ENDOTHELIALES ET PAR LE FIBRINOGEN
IN LANGUINO, Lucia, R.;
AUTIERI, Dario, C.;
PLOW, Edward, F.;
GELTSKY, John, E.
PA THE SCRIPPS RESEARCH INSTITUTE
LA English
DT Patent
PI WO 9325218 A1 19931223
DS AU CA FI JP NO AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
SE
AI WO 1993-US5610 A 19930611
PRAI US 1992-7/898,117 A 19920611
ICM A61K037-00
ICS A61K037-02; A61K039-395; C07K007-00; C07K015-28;
G01N033-53

L13 ANSWER 71 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993020200 PCTFULL ED 20020513
TIEN MODIFIED CELLS AND METHOD OF TREATMENT
TIFR CELLULES MODIFIEES ET PROCEDE DE TRAITEMENT
IN EVAN, Gerard, Ian
PA IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED;
EVAN, Gerard, Ian

LA English
DT Patent
PI WO 9320200 A1 19931014
DS W: GB JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
AI WO 1993-GB686 A 19930402
PRAI GB 1992-9207275.0 A 19920402
GB 1992-9207276.8 19920402
ICM C12N015-12
ICS C12N015-11; A61K037-02; A61K031-70; C12Q001-68; C12N005-10; C12N015-62

L13 ANSWER 72 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993019196 PCTFULL ED 20020513
TIEN ANTI-CD3 AGLYCOSYLATED IGG ANTIBODY
TIFR ANTICORPS IGG ANTI-CD3 AGLYCOSYLES
IN BOLT, Sarah, Louise;
CLARK, Michael, Ronald;
GORMAN, Scott, David;
ROUTLEDGE, Edward, Graham;
WALDMANN, Herman
PA BOLT, Sarah, Louise;
CLARK, Michael, Ronald;
GORMAN, Scott, David;
ROUTLEDGE, Edward, Graham;
WALDMANN, Herman

LA English
DT Patent
PI WO 9319196 A1 19930930
DS W: AU CA JP KR US AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
AI WO 1992-GB1933 A 19921021
PRAI GB 1992-9206422.9 19920324
ICM C12P021-08
ICS A61K039-395

L13 ANSWER 73 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993017715 PCTFULL ED 20020513
TIEN DIAGNOSTIC AND/OR THERAPEUTIC AGENTS, TARGETED TO NEOVASCULAR
TIFR AGENTS DIAGNOSTIQUES ET/OU THERAPEUTIQUES CIBLES SUR DES CELLULES
IN ENDOTHELIALES NEOVASCULAIRES
THORPE, Philip, E.;
BURROWS, Francis, J.
PA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM;
IMPERIAL CANCER RESEARCH TECHNOLOGY;
THORPE, Philip, E.;
BURROWS, Francis, J.
LA English
DT Patent
PI WO 9317715 A1 19930916
DS W: AT AU BB BG BR CA CH CZ DE DK ES FI GB HU JP KR LK LU MC
MN MW NL NO NZ PL PT RO RU SD SE SK UA US AT BE CH DE DK ES
FR GB GR IE IT LU MC NL PT SE BF BJ CP CG CI CM GA GN ML MR
SN TD TG
AI WO 1993-US1956 A 19930305
PRAI US 1992-7/846.349 19920305
ICM A61K047-48
ICS A61K049-00; A61K049-02

L13 ANSWER 74 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993016185 PCTFULL ED 20020513
TIEN BIOSYNTHETIC BINDING PROTEIN FOR CANCER MARKER
TIFR PROTEINE DE LIAISON BIOSYNTHETIQUE POUR MARQUEUR DE CANCER
IN HUSTON, James, S.;
HOUSTON, L., L.;
RING, David, B.;

PA OPPERMANN, Hermann
CREATIVE BIOMOLECULES, INC.;
CETUS ONCOLOGY CORPORATION
English
LA Patent
DT WO 9316185 A2 19930819
PI W: AU CA JP AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE
DS W: 1993-US1055 A 19930205
PRAI US 1992-831.967 19920206
ICM C12N015-13
ICS C12N015-62; C12P021-08; C07K013-00; C07K015-28; C12N001-21; G01N033-68; G01N033-574

L13 ANSWER 75 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993011236 PCTFULL ED 20020513
TIEN PRODUCTION OF ANTI-SELF ANTIBODIES FROM ANTIBODY
TIFR SEGMENT REPERTOIRES AND DISPLAYED ON PHAGE
IN PRODUCTION D'ANTICORPS ANTI-AUTO-ANTIGENES A PARTIR DE REPERTOIRES DE SEGMENTS D'ANTICORPS AFFICHES SUR PHAGE
GRIFFITHS, Andrew, David;
HOOGENDOORN, Hendricus, Renerus, Jacobus, Mattheus;
MARKS, James, David;
MCCAFFERTY, John;
WINTER, Gregory, Paul;
GRIGG, Geoffrey, Walter
PA MEDICAL RESEARCH COUNCIL;
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED;
GRIFFITHS, Andrew, David;
HOOGENDOORN, Hendricus, Renerus, Jacobus, Mattheus;
MARKS, James, David;
MCCAFFERTY, John;
WINTER, Gregory, Paul;
GRIGG, Geoffrey, Walter
LA English
DT Patent
PI WO 9311236 A1 19930610
DS W: AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KR LK LU MG
MN MW NL NO NZ PL PT RO RU SD SE US AT BE CH DE DK ES FR GB
GR IE IT LU MC NL PT SE BF BJ CP CG CI CM GA GN ML MR SN TD
TG
AI WO 1992-GB2240 A 19921202
PRAI GB 1991-9125579.4 19911202
GB 1991-9125582.8 19911202
GB 1992-9206318.9 19920324
GB 1992-9206372.6 19920324
GB 1992-PCT/GB92/01755 19920923
ICM C12N015-13
ICS C12N015-62; C07K013-00; C12P021-08; G01N033-531; G01N033-68

L13 ANSWER 76 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993009803 PCTFULL ED 20020513
TIEN FACTOR X-DERIVED POLYPEPTIDES AND ANTI-PEPTIDE ANTIBODIES,
TIFR SYSTEMS AND THERAPEUTIC METHODS FOR INHIBITING INFLAMMATION
IN POLYPEPTIDES DERIVES DU FACTEUR X ET ANTICORPS ANTIPEPTIDES, SYSTEMES ET
PROCEDES THERAPEUTIQUES SERVANT A INHIBER L'INFLAMMATION
ALTIERI, Dario, C.;
EDGINGTON, Thomas, S.;
FAIR, Daryl, S. +di
PA SCHAFFER, Susan, C. +ref;
THE SCRIPPS RESEARCH INSTITUTE;
ALTIERI, Dario, C.;
EDGINGTON, Thomas, S.
LA English
DT Patent
PI WO 9309803 A1 19930527

DS W: AU CA FI JP NO US AT BE CH DE DK ES FR GB GR IE IT LU MC NL
SE
AI WO 1992-US10068 A 19921120
PRAI US 1991-7/798,221 19911122
ICM A61K037-02
ICS C07K007-06; C07K007-08; C07K007-10

L13 ANSWER 77 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1993000356 PCTFULL ED 20020513
TIEN HYBRID PROTEINS CONTAINING BINDING SITES
TIFF PROTEINES HYBRIDES RENFERMANT DES SITES DE LIAISON
IN LERNHARDT, Waldegmar;
BOURDON, Mario;
YOUNDERIAN, Phil
CALIFORNIA INSTITUTE OF BIOLOGICAL RESEARCH;
LERNHARDT, Waldegmar;
BOURDON, Mario;
YOUNDERIAN, Phil
English
Patent
LA WO 9300356 AI 19930107
DT Patent
FI CA JP US AT BE CH DE DK ES FR GB GR IE IT LU MC NL SE
DS W: WO 1992-US5224 A 19920619
AI US 1991-720,222 19910621
PRAI C07K003-00
ICM C07K013-00; C12P021-00
ICS

L13 ANSWER 78 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1992006193 PCTFULL ED 20020513
TIEN ANTIBODIES DIRECTED AGAINST CD3
TIFF ANTICORPS A EFFICACITE ANTICORPTE A L'ANTIGENE CD3
IN GORMAN, Scott, David;
ROUTLEDGE, Edward, Graham;
WALDMANN, Herman
GORMAN, Scott, David;
ROUTLEDGE, Edward, Graham;
WALDMANN, Herman
English
Patent
LA WO 9206193 AI 19920416
DT Patent
FI AT AU BE CA CH DE DK ES FR GB GR IT JP KR LU NL SE US
DS W: WO 1991-GB1726 A 19911004
AI GB 1990-9021679.7 19901005
PRAI C12N015-13
ICM C07K015-28; C12P021-08; A61K039-395
ICS

L13 ANSWER 79 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1992006120 PCTFULL ED 20020513
TIEN ANTIGEN-ANTIBODY CONJUGATES
TIFF CONJUGUES ANTIGENES-ANTICORPS
IN MASON, Donald, William
PA MEDICAL RESEARCH COUNCIL;
MASON, Donald, William
English
Patent
LA WO 9206120 AI 19920416
DT Patent
FI AT AU BB BE BF BG BJ BR CA CF CG CH CI CM CS DE DE DK
DS DK ES FI FR CA GB GR GN GR HU IT JP KR LR LU MC MG
ML MN MR MW NL NO PL RO SD SE SN SU TD TG US
AI WO 1991-GB1641 A 19910924
PRAI GB 1990-9021210.1 19900928
ICM GB 1991-9110444.8 19910514
ICS C07K017-02
A61K039-00

L13 ANSWER 80 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991017258 PCTFULL ED 20020513
TIEN INHIBITORS OF FACTOR XII ACTIVATION AND APPLICATIONS THEREOF
TIFF INHIBITEURS DE L'ACTIVATION DU FACTEUR XII ET LEURS APPLICATIONS
IN NUIJENS, Jan, H.;
HUIJBREGTS, Cecile, C., M.;
HACK, C., Erik
English
Patent
LA WO 9117258 AI 19911114
DT Patent
FI AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
DS W: WO 1991-US2990 A 19910501
AI US 1990-521,820 19900510
PRAI C12P021-08
ICM C07K015-00; A61K039-395; C07K007-08
ICS

L13 ANSWER 81 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991012022 PCTFULL ED 20020513
TIEN IMMUNE COMPLEXES
TIFF COMPLEXES IMMUNS
IN HAMAGUCHI, Naoru;
SATO, Jun;
DOKEN, Kazuhiro;
IWASA, Susumu
English
Patent
LA WO 9112022 AI 19910822
DT Patent
FI AT BE CA CH DE DK ES FR GB GR IT JP KR LU NL SE US
DS W: WO 1991-JP136 A 19910205
AI JP 1990-2/27407 19900206
PRAI JP 1990-2/80182 19900328
ICM JP 1990-2/287648 19901024
ICS A61K047-48
A61K039-44; A61K037-52

L13 ANSWER 82 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991008774 PCTFULL ED 20020513
TIEN CYTOKINE ANTIBODY FOR THE TREATMENT OF SEPSIS
TIFF ANTICORPS DE CYTOKINE UTILISE DANS LE TRAITEMENT DE LA
IN SEPTICEMIE
AARDEN, Lucien, A.;
CREASEY, Abba, A.;
KOTHS, Kirston, E.
PA CETUS CORPORATION;
AARDEN, Lucien, A.
English
Patent
LA WO 9108774 AI 19910627
DT Patent
FI AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
DS W: WO 1990-US7411 A 19901213
AI US 1989-451,218 19891215
PRAI A61K039-395
ICM C12P021-08; C07K015-28
ICS

L13 ANSWER 83 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991006319 PCTFULL ED 20020513

TIE METHODS AND COMPOSITIONS FOR PROMOTING IMMUNOPOTENTIATION
TIFR PROCEDES ET COMPOSITIONS DE PROMOTION DE L'IMMUNOPOTENTIALISATION
IN BLUESTONE, Jeffery, A.
PA ARCH DEVELOPMENT CORPORATION
LA English
PT Patent
PI WO 9106319 A1 19910516
DS W: AT AU BE BG BJ BR CA CF CG CH CM DE DE DK DK ES
ES FI FR GA GB GR GR HU IT JP KP KR LK LU LU MC MG ML MR MW
NL NL NO RO SD SE SE SN SU TD TG
W: A 19901026
W: A 19901026
AI US 1989-429,729
PRAI US 1990-524,304
ICM A61K039-39
ICS A61K037-02; C07K015-00; A61K039-00; C12P021-08; A61K039-395;
A61K037-02

L13 ANSWER 84 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 1991002756 PCTFULL ED 20020513
TIFR PROHORMONE CLEAVAGE SITE BLOCKING ANTIBODY
TIE ANTICORPUS PROHORMONE POUR BLOCAGE DU SITE DE CLIVAGE
IN KRIEGLER, Michael;
PEREZ, Carl
PA CETUS CORPORATION
LA English
PT Patent
PI WO 9102756 A1 19910307
DS W: AT AU BE CH DE DK ES FR GB IT JP LU NL SE
W: A 19900813
AI US 1989-395,254
PRAI C07K015-28
ICM A61K039-395; G01N033-74; C12P021-08
ICS A61K039-395; G01N033-74; C12P021-08

L13 ANSWER 85 OF 92 PCTFULL COPYRIGHT 2003 Univentio
AN 199100360 PCTFULL ED 20020513
TIFR BISPECIFIC REAGENTS FOR AIDS THERAPY
TIE REACTIFS BISPECIFIQUES POUR LE TRAITEMENT DU SIDA
IN FANGER, Michael, W.;
GOYRE, Paul, M.;
DINCES, Nathan, B.
PA MEDAREX, INC.
LA English
PT Patent
PI WO 9100360 A1 19910110
DS W: AT AU BE CA CH DE DK ES FI FR GB IT JP LU NL NO SE
W: A 19900629
AI US 1989-373,905
PRAI C12P021-00
ICM C12N005-00; A61K039-395
ICS C12N005-00; A61K039-395

L13 ANSWER 86 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 95:804167 SCISEARCH
TIFR The Genuine Article (R) Number: TE709
TI PERFORMANCE OF CD3XCD19 BISPECIFIC MONOCLONAL-ANTIBODIES
IN B-CELL MALIGNANCY
AU HAAGEN I A (Reprint)
CS UNIV UTRECHT HOSP, DEPT IMMUNOL F03821, POSTBUS 85500, 3508 GA UTRECHT,
NETHERLANDS
CVA NETHERLANDS
SO LEUKEMIA & LYMPHOMA, (NOV 1995) Vol. 19, No. 5-6, pp. 381-393.
DT ISSN: 1042-8194.
FS General Review; Journal
LA LIFE; CLIN
REC No References Keyed

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
ANSWER 87 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 95:495351 SCISEARCH
TIFR The Genuine Article (R) Number: RJ663
TI CD8 T-CELL ACTIVATION AFTER INTRAVENOUS ADMINISTRATION OF CD3XCD19
BISPECIFIC ANTIBODY IN PATIENTS WITH
NON-HODGKIN-LYMPHOMA
AU DECAST G C (Reprint); HAAGEN I A; VANHOUTEN A A; KLEIN S C; DUITS A J;
DEWEGER R A; VROOM T M; CLARK M R; PHILLIPS J; VANDIJK A J G; DELAU W B M;
BAST B J E G
CS UNIV UTRECHT HOSP, DEPT HAEMATOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS
(Reprint); UNIV UTRECHT HOSP, DEPT IMMUNOL, UTRECHT, NETHERLANDS; UNIV
UTRECHT HOSP, DEPT PATHOL, 3508 GA UTRECHT, NETHERLANDS; UNIV CAMBRIDGE,
DEPT PATHOL, CAMBRIDGE, ENGLAND
CVA NETHERLANDS; ENGLAND
SO CANCER IMMUNOLOGY IMMUNOTHERAPY, (JUN 1995) Vol. 40, No. 6, pp. 390-396.
DT ISSN: 0340-7004.
FS Article; Journal
LA LIFE
REC No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
ANSWER 88 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 95:97858 SCISEARCH
TIFR The Genuine Article (R) Number: QC930
TI BISPECIFIC MONOCLONAL-ANTIBODY THERAPY OF B-
CELL MALIGNANCY
AU WEINER G J (Reprint); DECAST G C
CS UNIV IOWA, DEPT INTERNAL MED, C32K GH, IOWA CITY, IA, 52242 (Reprint)
CVA USA
SO LEUKEMIA & LYMPHOMA, (JAN 1995) Vol. 16, No. 3-4, pp. 199-207.
DT ISSN: 1042-8194.
FS General Review; Journal
LA LIFE; CLIN
REC No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
ANSWER 89 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 94:329243 SCISEARCH
TIFR The Genuine Article (R) Number: NN724
TI ROLE OF T-CELL SUBSETS IN THE BISPECIFIC ANTIBODY
(ANTIIDIOTYPE X ANTI-CD3) TREATMENT OF THE BCL(1) LYMPHOMA
AU DEMANET C; BRISSINCK J; LEE O; MOSER M; THIELEMAN K (Reprint)
CS FREE UNIV BRUSSELS, SCH MED, PHYSIOL LAB, LAARBEKLAN 103-E, B-1090
BRUSSELS, BELGIUM (Reprint); FREE UNIV BRUSSELS, SCH MED, PHYSIOL LAB,
B-1090 BRUSSELS, BELGIUM; FREE UNIV BRUSSELS, B-1060 RHODE ST GENESE,
BELGIUM
CVA BELGIUM
SO CANCER RESEARCH, (01 JUN 1994) Vol. 54, No. 11, pp. 2973-2978.
DT ISSN: 0008-5472.
FS Article; Journal
LA LIFE; CLIN
REC No References Keyed
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
ANSWER 90 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 93:729696 SCISEARCH
TIFR The Genuine Article (R) Number: MJ682
TI CYTOKINE RELEASE AFTER INTRAVENOUS ADMINISTRATION OF
BISPECIFIC ANTIBODY (CD3/CD19, SHR-1) - A PHASE-I STUDY
IN PATIENTS WITH CD19 POSITIVE B-CELL MALIGNANCIES

AU VANHOUTEN A A (Reprint); HAAGEN I A; CLARK M; GEERARS A; DELAU W; VROOM T
 M; BAST E J E G; DECAST G C
 CS UNIV UTRECHT HOSP, DEPT HEMATOL, 3511 GV UTRECHT, NETHERLANDS; UNIV
 UTRECHT HOSP, DEPT IMMUNOL, 3511 GV UTRECHT, NETHERLANDS; UNIV UTRECHT
 HOSP, DEPT PATHOL, 3511 GV UTRECHT, NETHERLANDS; UNIV CAMBRIDGE, DEPT
 PATHOL, CAMBRIDGE, ENGLAND
 CYA NETHERLANDS; ENGLAND
 SO BLOOD, (15 NOV 1993) Vol. 82, No. 10, Supp. 1, pp. A580.
 DT ISSN: 0006-4971.
 FS Conference; Journal
 LA LIFE; CLIN
 REC ENGLISH
 No References
 L13 ANSWER 91 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
 AN 93.454451 SCISEARCH
 GA The Genuine Article (R) Number: LN208
 TI CD30-ANTIGEN-SPECIFIC TARGETING AND ACTIVATION OF T-CELLS VIA MURINE
 BISPECIFIC MONOCLONAL-ANTIBODIES AGAINST CD3 AND CD28 -
 POTENTIAL USE FOR THE TREATMENT OF HODGKINS LYMPHOMA
 AU POHL C; DENFELD R; RENNER C; JUNG W; BOHLEN H; SAHIN U; HOMBACH A; VANLIER
 R; SCHWARZEN W; DIEHL V; PFREUNDSCHEID M (Reprint)
 CS UNIV SAARLAND, MED KLIN 1, W-6650 HOMBURG, GERMANY; UNIV COLOGNE, INNERE
 MED KLIN 1, W-5000 COLOGNE 41, GERMANY; NCB, AMSTERDAM, NETHERLANDS
 CYA GERMANY; NETHERLANDS
 SO INTERNATIONAL JOURNAL OF CANCER, (09 JUL 1993) Vol. 54, No. 5, pp.
 820-827.
 DT ISSN: 0020-7136.
 FS Article; Journal
 LA LIFE
 REC ENGLISH
 Reference Count: 32
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
 L13 ANSWER 92 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
 AN 92.687393 SCISEARCH
 GA The Genuine Article (R) Number: JY980
 TI TARGETED CYTOKINE PRODUCTION
 AU SEGAL D M (Reprint); QIAN J H; TITUS J A; MORENO M B; GEORGE A J T; JOST C
 R; KURCZ I; ELGAMIL M; WUNDERLICH J R
 CS NIH, EXPTL IMMUNOL BRANCH, BLDG 10, ROOM 4B17, BETHESDA, MD, 20892
 (Reprint)
 CYA USA
 SO INTERNATIONAL JOURNAL OF CANCER, (1992) Supp. 7, pp. 36-38.
 DT ISSN: 0020-7136.
 FS Article; Journal
 LA LIFE
 REC ENGLISH
 Reference Count: 21
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
 => d 90, 88, 86, 82, 61 ibib ab
 L13 ANSWER 90 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
 AN 93.729696 SCISEARCH
 GA The Genuine Article: MJ682
 TI CYTOKINE RELEASE AFTER INTRAVENOUS
 ADMINISTRATION OF BISPECIFIC ANTIBODY
 (CD3/CD19, SHR-1) - A PHASE-I STUDY IN PATIENTS WITH CD19
 POSITIVE B-CELL MALIGNANCIES
 AUTHOR: VANHOUTEN A A (Reprint); HAAGEN I A; CLARK M; GEERARS A;
 DELAU W; VROOM T M; BAST E J E G; DECAST G C
 CORPORATE SOURCE: UNIV UTRECHT HOSP, DEPT HEMATOL, 3511 GV UTRECHT,
 NETHERLANDS; UNIV UTRECHT HOSP, DEPT IMMUNOL, 3511 GV

UTRECHT, NETHERLANDS; UNIV UTRECHT HOSP, DEPT PATHOL, 3511
 GV UTRECHT, NETHERLANDS; UNIV CAMBRIDGE, DEPT PATHOL,
 CAMBRIDGE, ENGLAND
 NETHERLANDS; ENGLAND
 BLOOD, (15 NOV 1993) Vol. 82, No. 10, Supp. 1, pp. A580.
 DT ISSN: 0006-4971.
 FS Conference; Journal
 LA LIFE; CLIN
 REC ENGLISH
 No References
 L13 ANSWER 88 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
 AN 95.97858 SCISEARCH
 GA The Genuine Article: OC930
 TI BISPECIFIC MONOCLONAL-ANTIBODY THERAPY
 OF B-CELL MALIGNANCY
 AUTHOR: WEINER G J (Reprint); DECAST G C
 CORPORATE SOURCE: UNIV IOWA, DEPT INTERNAL MED, C32K GH, IOWA CITY, IA,
 52242 (Reprint)
 USA
 COUNTRY OF AUTHOR: LEUKEMIA & LYMPHOMA, (JAN 1995) Vol. 16, No. 3-4, pp.
 199-207.
 DT ISSN: 1042-8194.
 FS General Review; Journal
 LA LIFE; CLIN
 REC ENGLISH
 No References Keyed
 ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS
 AB Bispecific monoclonal antibodies (bsAbs) that
 recognize CD3 with one arm and a tumor associated antigen with the other
 arm can retarget T-cells toward tumor cells in an MHC independent manner,
 thereby combining the specificity of monoclonal antibodies with
 the power of the cellular immune system. B-cell
 malignancies are particularly attractive as targets for anti-CD3-based
 bsAb therapy because of their sensitivity to other forms of
 antibody therapy, and the extent to which B-
 cells and T-cells communicate at the molecular level. BsAbs that
 recognize CD3 and a number of antigens on malignant B-
 cells have been shown in vitro to be capable of retargeting
 T-cells. In animal models of B-cell malignancy, bsAb
 can eliminate tumor loads that are resistant to unmodified monoclonal
 antibody therapy. Ongoing early clinical trials in advanced
 B-cell lymphoma indicate CD3-based bsAbs have
 significant biologic effects, and suggest they have anti-tumor activity as
 well. A number of significant questions relating to bsAb therapy of
 B-cell malignancies remain. It is unclear what role both
 endogenously produced and exogenously administered cytokines are
 likely to play. Further exploration of whether bsAb can induce T-cells to
 target to tumor will also be required before the true promise of this
 novel form of immunotherapy can be determined.
 L13 ANSWER 86 OF 92 SCISEARCH COPYRIGHT 2003 ISI (R)
 AN 95.804167 SCISEARCH
 GA The Genuine Article: TE709
 TI PERFORMANCE OF CD3/CD19 BISPECIFIC MONOCLONAL-
 ANTIBODIES IN B-CELL
 MALIGNANCY
 AUTHOR: HAAGEN I A (Reprint)
 CORPORATE SOURCE: UNIV UTRECHT HOSP, DEPT IMMUNOL F03821, POSTBUS 85500,
 3508 GA UTRECHT, NETHERLANDS (Reprint)
 NETHERLANDS
 COUNTRY OF AUTHOR: LEUKEMIA & LYMPHOMA, (NOV 1995) Vol. 19, No. 5-6, pp.
 381-393.
 DT ISSN: 1042-8194.
 FS General Review; Journal

FILE SEGMENT: LIFE; CLIN
LANGUAGE: ENGLISH
REFERENCE COUNT: No References keyed

AB. Bispecific monoclonal antibodies, with a dual specificity for tumor associated antigens on target cells and for surface markers on immune effector cells, have been shown (in vitro) to be effective in directing and triggering effector cells to kill target cells resulting in target cell lysis. Bispecific monoclonal antibodies (BsAb) against the CD3 antigen on T cells and the CD19 antigen on B cell were developed. Data obtained by in vitro experiments might indicate that clinical responses in BsAb immunotherapy, will only be obtained in patients with minimal tumor load and may need additional T cell stimulation via cytokines such as IL-2. Although these experiments have shown us their limitations, they also include the promise of BsAb-directed immunotherapy in B cell malignancy as further demonstrated during a Phase I trial, showing little toxicity. Clearly, much remains to be done before this BsAb is routinely used for therapy, but, the results presented show that the CD3CD19 BsAb has a potential as a therapeutic agent in B cell malignancy. This report describes the experiments performed to test a new immunotherapeutic approach for the treatment of B cell malignancy. Bispecific antibodies are described that can target cytotoxic T cells to tumor cells and elicit a cytolytic action towards these cancer cells.

L13 ANSWER 82 OF 92 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1991008774 PCTFULL ED 20020513
TITLE (ENGLISH): CYTOKINE ANTIBODY FOR THE TREATMENT OF SEPSIS
TITLE (FRENCH): ANTICORPS DE CYTOKINE UTILISE DANS LE TRAITEMENT DE LA SEPTICEMIE
INVENTOR (S): AARDEN, Lucien, A.;
CREASEY, Abla, A.;
KOTHS, Kirston, E.;
CETUS CORPORATION;
AARDEN, Lucien, A.
PATENT ASSIGNEE(S): English
PATENT TYPE: Patent
LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION: English
PATENT INFORMATION: Patent

DESIGNATED STATES
W:
AT AU BE CA CH DE DK ES FR GB GR IT JP LU NL SE
US 1990-US7411 A 19901213
US 1989-451,218 19891215
ABEN Compositions and methods for prophylactically or therapeutically treating sepsis consisting of antibody to IL-6 and/or M-CSF wherein the antibodies are administered alone or in combination. de la septicemie, comprenant un anticorps contre IL-6 et/ou les facteurs de croissance de macrophages, dans lesquels les anticorps sont administrés seuls ou de maniere combinee.

ABFR Compositions et procedes de traitements prophylactiques ou therapeutiques de la septicemie, comprenant un anticorps contre IL-6 et/ou les facteurs de croissance de macrophages, dans lesquels les anticorps sont administrés seuls ou de maniere combinee.

L13 ANSWER 61 OF 92 PCTFULL COPYRIGHT 2003 Univentio
ACCESSION NUMBER: 1994013804 PCTFULL ED 20020513
TITLE (ENGLISH): MULTIVALENT AND MULTISPECIFIC BINDING PROTEINS, THEIR MANUFACTURE AND USE
TITLE (FRENCH): PROTEINES DE LIAISON MULTIVALENTES ET MULTISPECIFIQUES, LEUR FABRICATION ET LEUR UTILISATION
INVENTOR (S): HOLLIGER, Kaspar-Philipp;
GRIFFITHS, Andrew, David;

HOGENBOOM, Hendricus, Renerus, Jacobus, Matheus;
MALMQVIST, Magnus;
MARKS, James, David;
MCGUINNESS, Brian, Timothy;
POPE, Anthony, Richard;
PROSPERO, Terence, Derek;
WINTER, Gregory, Paul
CAMBRIDGE ANTIBODY TECHNOLOGY LIMITED;
MEDICAL RESEARCH COUNCIL;
HOLLIGER, Kaspar-Philipp;
GRIFFITHS, Andrew, David;
HOGENBOOM, Hendricus, Renerus, Jacobus, Matheus;
MALMQVIST, Magnus;
MARKS, James, David;
MCGUINNESS, Brian, Timothy;
POPE, Anthony, Richard;
PROSPERO, Terence, Derek;
WINTER, Gregory, Paul
English
Patent

PATENT ASSIGNEE(S):

LANGUAGE OF PUBL.: English
DOCUMENT TYPE: Patent
PATENT INFORMATION: English
PATENT INFORMATION: Patent

DESIGNATED STATES
W:
AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR
KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA
US UZ VN AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT
SE BF BJ CF CG CI CM GN ML MR NE SN TD TG
WO 1993-GB2492 A 19931203
GB 1992-9225453.1 19921204
GB 1993-9300816.7 19930116
GB 1993-93303614.7 19930510
GB 1993-9319969.3 19930922
ABEN Polypeptides comprising a first domain, which comprises a binding region of an immunoglobulin heavy chain variable region, and a second domain, which comprises a binding region of an immunoglobulin light chain variable region, the domains being linked but incapable of associating with each other to form an antigen binding site, associate to form as dimers, which may be multivalent or have multispecificity. The domains may be linked by a short peptide linker or may be joined directly together. Bispecific dimers may have longer linkers. Methods of preparation of the polypeptides and multimers and diverse repertoires thereof, and their display on the surface of bacteriophage for easy selection of binders of interest, are disclosed. along with many utilities. Des polypeptides comprenant un premier domaine presentant une region de fixation de la region variable d'une chaine lourde d'immunoglobuline, et un deuxieme domaine presentant une region de fixation de la region variable d'une chaine legere d'immunoglobuline, lesdits domaines etant lies mais incapables de s'associer pour former un site de fixation d'antigene, s'associent pour former des multimeres de fixation d'antigene tels que des dimeres, lesquels peuvent etre multivalents ou a specificite multiple. Les domaines peuvent etre lies par un lieur peptidique court ou unis directement. Les dimeres bispecifiques peuvent avoir des lieurs plus longs. Des procedes de

preparation desdits polypeptides et multimeres ainsi que de leurs divers
repertoires, leur
utilisation a la surface d'un bacteriophage afin de faciliter la
selection des lieurs selon
l'invention ainsi que leurs nombreuses applications sont decrits.

=> 2- Logging off of STN---

Connection closed by remote host
END

Unable to generate the STN prompt.
Exiting the script...